CTLA-4	B-protein
-Mediated	O
inhibition	O
of	O
early	O
events	O
of	O
T	O
cell	O
proliferation	O
.	O

CTLA-4	B-protein
engagement	O
by	O
mAbs	B-protein
inhibits	O
,	O
while	O
CD28	B-protein
enhances	O
,	O
IL-2	B-protein
production	O
and	O
proliferation	O
upon	O
T	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4	B-protein
-mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
using	O
Ab	O
cross-linking	O
.	O

CTLA-4	B-protein
ligation	O
inhibited	O
CD3/	O
CD28	B-protein
-induced	O
IL-2	B-RNA
mRNA	I-RNA
accumulation	O
by	O
inhibiting	O
IL-2	B-protein
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF-AT	B-protein
accumulation	O
in	O
the	O
nuclei	O
.	O

However	O
,	O
CTLA-4	B-protein
ligation	O
did	O
not	O
appear	O
to	O
affect	O
the	O
CD28	B-protein
-mediated	O
stabilization	O
of	O
IL-2	B-RNA
mRNA	I-RNA
.	O

Further	O
,	O
CTLA-4	B-protein
engagement	O
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	O
the	O
production	O
of	O
cyclin	B-protein
D3	I-protein
,	O
cyclin-dependent	B-protein
kinase	I-protein
(	B-protein
cdk	I-protein
)	I-protein
4	I-protein
,	O
and	O
cdk6	B-protein
when	O
the	O
T	B-cell_type
cells	I-cell_type
were	O
stimulated	O
with	O
anti-CD3/CD28	B-protein
and	O
with	O
anti-CD3	B-protein
alone	O
.	O

These	O
results	O
indicate	O
that	O
CTLA-4	B-protein
signaling	O
inhibits	O
events	O
early	O
in	O
T	O
cell	O
activation	O
both	O
at	O
IL-2	B-protein
transcription	O
and	O
at	O
the	O
level	O
of	O
IL-2	B-protein
-independent	O
events	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
does	O
not	O
simply	O
oppose	O
CD28	B-protein
-mediated	O
costimulation	O
.	O

_-	NULL
.	NULL

_	NULL
The	NULL
Attune	NULL
``	NULL
NXT	NULL
Flow	NULL
Cytometer	NULL
system	NULL
invitrogen	NULL
by	NULL
Thermo	NULL
Fisher	NULL
Scientific	NULL
CTLA-4-Mediated	NULL
Inhibition	NULL
of	NULL
Early	NULL
Events	NULL
j	NULL
Immunolo	NULL
gy	NULL
of	NULL
T	NULL
Cell	NULL
Proliferation	NULL
AP	NULL
“	NULL
meJournal	NULL
o	NULL
\ge	NULL
?	NULL

u	NULL
Monika	NULL
C.	NULL
Brunner	NULL
,	NULL
Cynthia	NULL
A	NULL
.	NULL

Chambers	NULL
,	NULL
Francis	NULL
Ka-Ming	NULL
200.	NULL
woe	NULL
Chan	NULL
,	NULL
Jeff	NULL
Hanke	NULL
,	NULL
Astar	NULL
Winoto	NULL
and	NULL
James	NULL
P.	NULL
Allison	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:5813-5820	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/10/5813	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
70	NULL
articles	NULL
,	NULL
43	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/10/5813.full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
CTLA-4-Mediated	NULL
Inhibition	NULL
of	NULL
Early	NULL
Events	NULL
of	NULL
T	NULL
Cell	NULL
Proliferation	NULL
Monika	NULL
C.	NULL
Brunner	NULL
,	NULL
``	NULL
*	NULL
Cynthia	NULL
A	NULL
.	NULL

Chambers	NULL
,	NULL
*	NULL
Francis	NULL
Ka-Ming	NULL
Chan	NULL
,	NULL
*	NULL
Jeff	NULL
Hanke	NULL
,	NULL
``	NULL
Astar	NULL
Winoto	NULL
,	NULL
*	NULL
and	NULL
James	NULL
P.	NULL
Allison**	NULL
CTLA-4	NULL
engagement	NULL
by	NULL
mAbs	NULL
inhibits	NULL
,	NULL
while	NULL
CD28	NULL
enhances	NULL
,	NULL
IL-2	NULL
production	NULL
and	NULL
proliferation	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
analyzed	NULL
the	NULL
mechanisms	NULL
involved	NULL
in	NULL
CTLA-4-mediated	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
using	NULL
Ab	NULL
cross-linking	NULL
.	NULL

CTLA-4	NULL
ligation	NULL
inhibited	NULL
CD3/CD28-induced	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
by	NULL
inhibiting	NULL
IL-2	NULL
transcription	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
mediated	NULL
in	NULL
part	NULL
through	NULL
decreasing	NULL
NF-AT	NULL
accumulation	NULL
in	NULL
the	NULL
nuclei	NULL
.	NULL

However	NULL
,	NULL
CTLA-4	NULL
ligation	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
affect	NULL
the	NULL
CD28-mediated	NULL
stabilization	NULL
of	NULL
IL-2	NULL
mRNA	NULL
.	NULL

Further	NULL
,	NULL
CTLA-4	NULL
engagement	NULL
inhibited	NULL
progression	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
by	NULL
inhibiting	NULL
the	NULL
production	NULL
of	NULL
cyclin	NULL
D3	NULL
,	NULL
cyclin-dependent	NULL
kinase	NULL
(	NULL
edk	NULL
)	NULL
4	NULL
,	NULL
and	NULL
edk6	NULL
when	NULL
the	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3/CD28	NULL
and	NULL
with	NULL
anti-CD3	NULL
alone	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
CTLA-4	NULL
signaling	NULL
inhibits	NULL
events	NULL
early	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
both	NULL
at	NULL
IL-2	NULL
transcription	NULL
and	NULL
at	NULL
the	NULL
level	NULL
of	NULL
IL-2-independent	NULL
events	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
and	NULL
does	NULL
not	NULL
simply	NULL
oppose	NULL
CD28-mediated	NULL
costimulation	NULL
.	NULL

-	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
;	NULL
5813-5820.	NULL
ptimal	NULL
activation	NULL
and	NULL
differentiation	NULL
of	NULL
naive	NULL
CD4	NULL
T	NULL
O	NULL
cells	NULL
to	NULL
cytokine-producing	NULL
effector	NULL
cells	NULL
requires	NULL
en-	NULL
gagement	NULL
of	NULL
the	NULL
TCR/CD3	NULL
complex	NULL
and	NULL
the	NULL
costimulatory	NULL
molecule	NULL
CD28	NULL
.	NULL

The	NULL
function	NULL
of	NULL
CD28	NULL
homologue	NULL
CTLA-4	NULL
has	NULL
been	NULL
more	NULL
controversial	NULL
.	NULL

Although	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
share	NULL
the	NULL
same	NULL
ligands	NULL
,	NULL
namely	NULL
B7.1	NULL
and	NULL
B7.2	NULL
,	NULL
CTLA-4	NULL
binds	NULL
with	NULL
an	NULL
affinity	NULL
that	NULL
is	NULL
10-	NULL
to	NULL
20-fold	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
CD28	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
and	NULL
has	NULL
a	NULL
unique	NULL
expression	NULL
pattern	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

With	NULL
the	NULL
exception	NULL
of	NULL
two	NULL
reports	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
,	NULL
recent	NULL
evidence	NULL
indicates	NULL
that	NULL
CTLA-4	NULL
plays	NULL
an	NULL
inhibitory	NULL
rather	NULL
than	NULL
a	NULL
positive	NULL
costimulatory	NULL
role	NULL
in	NULL
regulating	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

This	NULL
idea	NULL
was	NULL
initially	NULL
suggested	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
soluble	NULL
anti-CTLA-4	NULL
Abs	NULL
,	NULL
both	NULL
intact	NULL
and	NULL
Fab	NULL
fragments	NULL
,	NULL
augment	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
vitro	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

Blocking	NULL
CTLA-4/B7	NULL
interaction	NULL
in	NULL
vivo	NULL
also	NULL
increases	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
antigenic	NULL
challenges	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
and	NULL
enhances	NULL
T	NULL
cell-mediated	NULL
tumor	NULL
rejection	NULL
,	NULL
parasite	NULL
clearing	NULL
(	NULL
11-13	NULL
)	NULL
,	NULL
and	NULL
autoimmune	NULL
disease	NULL
progression	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

14	NULL
,	NULL
and	NULL
Ref	NULL
.	NULL

15	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
CTLA-4	NULL
cross-linking	NULL
in	NULL
conjunction	NULL
with	NULL
anti-CD3/CD28	NULL
cross-linking	NULL
results	NULL
in	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
IL-2	NULL
secretion	NULL
by	NULL
murine	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
16	NULL
,	NULL
17	NULL
)	NULL
and	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
a	NULL
positive	NULL
costimulatory	NULL
role	NULL
for	NULL
CTLA-4	NULL
was	NULL
indicated	NULL
by	NULL
the	NULL
absence	NULL
of	NULL
B7-dependent	NULL
responses	NULL
in	NULL
CD28-deficient	NULL
mice	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
CTLA-4	NULL
blockade	NULL
exacerbates	NULL
graft-vs-host	NULL
disease	NULL
generated	NULL
with	NULL
grafts	NULL
from	NULL
CD28~'~	NULL
mice	NULL
(	NULL
20	NULL
)	NULL
,	NULL
and	NULL
allograft	NULL
and	NULL
tumor	NULL
re	NULL
*Howard	NULL
Hughes	NULL
Medical	NULL
Research	NULL
Institute	NULL
,	NULL
Cancer	NULL
Research	NULL
Laboratory	NULL
,	NULL
Department	NULL
of	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Berkeley	NULL
,	NULL
CA	NULL
94720	NULL
;	NULL
and	NULL
*Central	NULL
Division	NULL
,	NULL
Pfizer	NULL
Inc.	NULL
,	NULL
Groton	NULL
,	NULL
CT	NULL
06340	NULL
Received	NULL
for	NULL
publication	NULL
November	NULL
24	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
February	NULL
26	NULL
,	NULL
1999	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Bundesministerium	NULL
fir	NULL
Bildung	NULL
und	NULL
Forschung	NULL
(	NULL
BMBF	NULL
)	NULL
fellowship	NULL
(	NULL
to	NULL
M.C.B	NULL
.	NULL
)	NULL

,	NULL
Human	NULL
Frontier	NULL
Science	NULL
Program	NULL
Organization	NULL
(	NULL
to	NULL
C.A.C	NULL
.	NULL
)	NULL

,	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
CA40041	NULL
(	NULL
to	NULL
J.P.A	NULL
.	NULL
)	NULL

.	NULL

James	NULL
P.	NULL
Allison	NULL
is	NULL
an	NULL
investigator	NULL
of	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
.	NULL

2	NULL
Current	NULL
address	NULL
:	NULL
Deutsches	NULL
Rheuma-Forschungszentrum	NULL
Berlin	NULL
,	NULL
Hannoversche	NULL
Str	NULL
.	NULL

27	NULL
,	NULL
10115	NULL
Berlin	NULL
,	NULL
Germany	NULL
°	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
James	NULL
P.	NULL
Allison	NULL
,	NULL
447	NULL
LSA	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Berkeley	NULL
,	NULL
CA	NULL
94720	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
jallison	NULL
@	NULL
uclink4.berkeley.edu	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
jection	NULL
in	NULL
CD28	NULL
'~	NULL
mice	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
mice	NULL
with	NULL
a	NULL
null	NULL
mutation	NULL
in	NULL
CTLA-4	NULL
display	NULL
a	NULL
massive	NULL
polyclonal	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
expansion	NULL
that	NULL
results	NULL
in	NULL
a	NULL
dramatic	NULL
,	NULL
fatal	NULL
lymphoproliferative	NULL
disorder	NULL
(	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

The	NULL
dramatic	NULL
phenotype	NULL
of	NULL
these	NULL
mice	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
due	NULL
to	NULL
a	NULL
defect	NULL
in	NULL
thymic	NULL
development	NULL
or	NULL
selection	NULL
,	NULL
since	NULL
both	NULL
appear	NULL
normal	NULL
in	NULL
the	NULL
CTLA-4	NULL
null	NULL
mice	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Rather	NULL
,	NULL
this	NULL
activation	NULL
is	NULL
mediated	NULL
by	NULL
CD28-dependent	NULL
activation	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
of	NULL
peripheral	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Together	NULL
,	NULL
these	NULL
observations	NULL
provide	NULL
a	NULL
compelling	NULL
case	NULL
for	NULL
an	NULL
inhibitory	NULL
role	NULL
for	NULL
CTLA-4	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

The	NULL
stage	NULL
at	NULL
which	NULL
CTLA-4	NULL
exerts	NULL
its	NULL
inhibitory	NULL
effects	NULL
has	NULL
not	NULL
been	NULL
clearly	NULL
defined	NULL
.	NULL

CD28	NULL
is	NULL
constitutively	NULL
expressed	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
CTLA-4	NULL
is	NULL
expressed	NULL
at	NULL
low	NULL
,	NULL
undetectable	NULL
levels	NULL
on	NULL
naive	NULL
T	NULL
cells	NULL
and	NULL
is	NULL
induced	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
29-33	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
CTLA-4	NULL
is	NULL
not	NULL
readily	NULL
detectable	NULL
on	NULL
resting	NULL
cells	NULL
and	NULL
is	NULL
not	NULL
expressed	NULL
at	NULL
maximal	NULL
amounts	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
until	NULL
about	NULL
48	NULL
h	NULL
after	NULL
T	NULL
cell	NULL
activation	NULL
has	NULL
led	NULL
to	NULL
the	NULL
notion	NULL
that	NULL
its	NULL
function	NULL
is	NULL
to	NULL
regulate	NULL
ongoing	NULL
T	NULL
cell	NULL
responses	NULL
(	NULL
34	NULL
)	NULL
.	NULL

However	NULL
,	NULL
CTLA-4	NULL
mRNA	NULL
is	NULL
already	NULL
detectable	NULL
within	NULL
1	NULL
h	NULL
after	NULL
activation	NULL
in	NULL
previously	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
and	NULL
is	NULL
detectable	NULL
by	NULL
PCR	NULL
in	NULL
samples	NULL
prepared	NULL
from	NULL
purified	NULL
naive	NULL
murine	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
M.C.B	NULL
.	NULL

and	NULL
J.P.A	NULL
.	NULL

,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Also	NULL
,	NULL
CTLA-4	NULL
has	NULL
a	NULL
unique	NULL
intracellular	NULL
localization	NULL
,	NULL
with	NULL
the	NULL
majority	NULL
of	NULL
the	NULL
CTLA-4	NULL
protein	NULL
being	NULL
retained	NULL
inside	NULL
the	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
3	NULL
,	NULL
4	NULL
,	NULL
33	NULL
)	NULL
.	NULL

These	NULL
observations	NULL
suggest	NULL
that	NULL
CTLA-4	NULL
is	NULL
present	NULL
at	NULL
physiologically	NULL
significant	NULL
levels	NULL
and	NULL
may	NULL
regulate	NULL
T	NULL
cell	NULL
responses	NULL
much	NULL
earlier	NULL
than	NULL
indicated	NULL
by	NULL
cell	NULL
surface	NULL
expression	NULL
.	NULL

Although	NULL
it	NULL
was	NULL
initially	NULL
reported	NULL
that	NULL
CTLA-4	NULL
cross-linking	NULL
induced	NULL
apoptosis	NULL
(	NULL
35	NULL
)	NULL
,	NULL
other	NULL
studies	NULL
showed	NULL
that	NULL
CTLA-4	NULL
engagement	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
prevents	NULL
progression	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
without	NULL
causing	NULL
apoptosis	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Rather	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
CTLA-4	NULL
engagement	NULL
inhibits	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
events	NULL
,	NULL
including	NULL
the	NULL
induction	NULL
of	NULL
IL-2R	NULL
«	NULL
-chain	NULL
and	NULL
CD69	NULL
expression	NULL
,	NULL
the	NULL
increase	NULL
in	NULL
T	NULL
cell	NULL
volume	NULL
,	NULL
and	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
(	NULL
16-18	NULL
)	NULL
.	NULL

The	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
these	NULL
responses	NULL
are	NULL
un-known	NULL
.	NULL

Optimal	NULL
IL-2	NULL
secretion	NULL
requires	NULL
CD28-mediated	NULL
costimulation	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

36	NULL
)	NULL
.	NULL

Two	NULL
mechanisms	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
account	NULL
for	NULL
the	NULL
enhanced	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
upon	NULL
co-stimulation	NULL
:	NULL
prolongation	NULL
of	NULL
the	NULL
IL-2	NULL
mRNA	NULL
half-life	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
and	NULL
0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5814	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
(	NULL
39	NULL
)	NULL
,	NULL
perhaps	NULL
as	NULL
a	NULL
result	NULL
of	NULL
increased	NULL
levels	NULL
of	NULL
the	NULL
transcription	NULL
factors	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
in	NULL
the	NULL
nucleus	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Cell	NULL
cycle	NULL
progression	NULL
is	NULL
regulated	NULL
by	NULL
a	NULL
series	NULL
of	NULL
cyclins	NULL
,	NULL
cyclin	NULL
kinases	NULL
,	NULL
and	NULL
inhibitors	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

41	NULL
)	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
G/G	NULL
,	NULL
to	NULL
S	NULL
transition	NULL
is	NULL
mediated	NULL
early	NULL
in	NULL
G	NULL
,	NULL
,	NULL
mostly	NULL
through	NULL
a	NULL
combination	NULL
of	NULL
cyclin	NULL
D2/D3	NULL
with	NULL
cyclin-dependent	NULL
kinase	NULL
(	NULL
edk	NULL
)	NULL
*	NULL
4/cdk6	NULL
and	NULL
cyclin	NULL
E/cdk2	NULL
in	NULL
late	NULL
G	NULL
,	NULL
(	NULL
see	NULL
Refs	NULL
.	NULL

56	NULL
,	NULL
57	NULL
,	NULL
62-64	NULL
)	NULL
.	NULL

How	NULL
CTLA-4	NULL
cross-linking	NULL
affects	NULL
these	NULL
pathways	NULL
at	NULL
the	NULL
molecular	NULL
levels	NULL
is	NULL
not	NULL
known	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
examine	NULL
the	NULL
mechanisms	NULL
involved	NULL
in	NULL
CTLA-A-mediated	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Using	NULL
Ab-coated	NULL
microspheres	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
CTLA-4	NULL
cross-linking	NULL
inhibits	NULL
anti-CD3/CD28	NULL
Ab-induced	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
.	NULL

CTLA-4	NULL
engagement	NULL
inhibits	NULL
luciferase	NULL
production	NULL
by	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
mice	NULL
bearing	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
indicating	NULL
that	NULL
IL-2	NULL
gene	NULL
transcription	NULL
is	NULL
inhibited	NULL
.	NULL

This	NULL
effect	NULL
appears	NULL
to	NULL
be	NULL
at	NULL
least	NULL
partially	NULL
due	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
NF-AT	NULL
nuclear	NULL
translocation	NULL
.	NULL

Conversely	NULL
,	NULL
the	NULL
CD28-mediated	NULL
IL-2	NULL
mRNA	NULL
stabilization	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
affected	NULL
by	NULL
CTLA-4	NULL
cross-linking	NULL
.	NULL

CTLA-4	NULL
engagement	NULL
also	NULL
prevents	NULL
progression	NULL
through	NULL
the	NULL
cell	NULL
cycle	NULL
,	NULL
by	NULL
inhibiting	NULL
the	NULL
production	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
proteins	NULL
cyclin	NULL
D3	NULL
and	NULL
edk4	NULL
,	NULL
which	NULL
are	NULL
partially	NULL
IL-2-dependent	NULL
,	NULL
and	NULL
edk6	NULL
,	NULL
which	NULL
is	NULL
IL-2-independent	NULL
,	NULL
and	NULL
altering	NULL
the	NULL
degradation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
inhibitor	NULL
p27	NULL
.	NULL

Interestingly	NULL
,	NULL
CTLA-4A-mediated	NULL
effects	NULL
on	NULL
cell	NULL
cycle	NULL
proteins	NULL
were	NULL
observed	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
via	NULL
CD3	NULL
alone	NULL
,	NULL
suggesting	NULL
CTLA-4	NULL
can	NULL
inhibit	NULL
CD28-independent	NULL
pathways	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Mice	NULL
BALB/c	NULL
mice	NULL
were	NULL
purchased	NULL
from	NULL
The	NULL
Jackson	NULL
Laboratory	NULL
(	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

The	NULL
IL-2P-luc	NULL
transgene	NULL
was	NULL
generated	NULL
by	NULL
inserting	NULL
a	NULL
2160-bp	NULL
genomic	NULL
fragment	NULL
from	NULL
the	NULL
human	NULL
growth	NULL
hormone	NULL
gene	NULL
(	NULL
42	NULL
)	NULL
into	NULL
pBlue-script	NULL
SK	NULL
(	NULL
-	NULL
)	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
and	NULL
the	NULL
firefly	NULL
luciferase	NULL
gene	NULL
was	NULL
cloned	NULL
upstream	NULL
of	NULL
the	NULL
Ag/	NULL
gene	NULL
to	NULL
yield	NULL
vector	NULL
pSKluxhgh	NULL
.	NULL

The	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
murine	NULL
IL-2	NULL
gene	NULL
(	NULL
positions	NULL
-590	NULL
bp	NULL
to	NULL
+40	NULL
bp	NULL
)	NULL
(	NULL
43	NULL
)	NULL
was	NULL
PCR-amplified	NULL
from	NULL
murine	NULL
genomic	NULL
DNA	NULL
(	NULL
Clontech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

The	NULL
mouse	NULL
x	NULL
globulin	NULL
gene	NULL
matrix	NULL
association	NULL
region	NULL
(	NULL
positions	NULL
2849-3764	NULL
;	NULL
kindly	NULL
provided	NULL
by	NULL
William	NULL
Gar-rard	NULL
,	NULL
University	NULL
of	NULL
Texas	NULL
Southwestern	NULL
,	NULL
Dallas	NULL
,	NULL
TX	NULL
(	NULL
44	NULL
)	NULL
)	NULL
was	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
to	NULL
ensure	NULL
stable	NULL
integration	NULL
into	NULL
the	NULL
genomic	NULL
DNA	NULL
.	NULL

The	NULL
transgene	NULL
was	NULL
excised	NULL
from	NULL
the	NULL
final	NULL
vector	NULL
,	NULL
purified	NULL
,	NULL
and	NULL
injected	NULL
into	NULL
embryos	NULL
by	NULL
standard	NULL
techniques	NULL
.	NULL

Transgene	NULL
incorporation	NULL
was	NULL
assessed	NULL
by	NULL
Southern	NULL
blot	NULL
analysis	NULL
.	NULL

To	NULL
test	NULL
for	NULL
appropriate	NULL
transgene	NULL
expression	NULL
,	NULL
splenocytes	NULL
from	NULL
the	NULL
transgenic	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
2	NULL
wM	NULL
;	NULL
both	NULL
from	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
or	NULL
anti-CD3	NULL
Ab	NULL
(	NULL
100	NULL
ng/ml	NULL
;	NULL
Cappel	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
plus	NULL
PMA	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
isolated	NULL
at	NULL
various	NULL
time	NULL
points	NULL
after	NULL
activation	NULL
and	NULL
tested	NULL
for	NULL
luciferase	NULL
expression	NULL
.	NULL

In	NULL
all	NULL
experiments	NULL
,	NULL
the	NULL
transgene	NULL
responded	NULL
to	NULL
the	NULL
stimuli	NULL
similarly	NULL
to	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Mice	NULL
were	NULL
maintained	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
Animal	NULL
Care	NULL
and	NULL
Use	NULL
regulations	NULL
of	NULL
the	NULL
University	NULL
of	NULL
California	NULL
(	NULL
Berkeley	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Abs	NULL
and	NULL
reagents	NULL
RPMI	NULL
1640	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Walkersville	NULL
,	NULL
MD	NULL
)	NULL
was	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
calf	NULL
serum	NULL
(	NULL
HyClone	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
2	NULL
uM	NULL
2-ME	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
2	NULL
uM	NULL
L-glutamine	NULL
,	NULL
and	NULL
100	NULL
U/ml	NULL
antibiotics	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

The	NULL
Abs	NULL
used	NULL
for	NULL
activation	NULL
were	NULL
:	NULL
anti-CD3	NULL
(	NULL
hybridoma	NULL
500A2	NULL
(	NULL
45	NULL
)	NULL
)	NULL
,	NULL
anti-CD28	NULL
(	NULL
hybridoma	NULL
37.N.51.1	NULL
(	NULL
46	NULL
)	NULL
)	NULL
,	NULL
anti-CTLA-4	NULL
(	NULL
hybridoma	NULL
9H10.11G3	NULL
(	NULL
8	NULL
)	NULL
)	NULL
,	NULL
and	NULL
aVy3	NULL
(	NULL
hybridoma	NULL
536	NULL
(	NULL
47	NULL
)	NULL
)	NULL
.	NULL

Anti-class	NULL
II	NULL
MHC	NULL
(	NULL
hy-bridomas	NULL
28-16-8s	NULL
(	NULL
48	NULL
)	NULL
)	NULL
and	NULL
BP107	NULL
(	NULL
49	NULL
)	NULL
)	NULL
,	NULL
and	NULL
anti-CD8	NULL
(	NULL
50	NULL
)	NULL
,	NULL
and	NULL
complement	NULL
(	NULL
Sigma	NULL
)	NULL
were	NULL
used	NULL
for	NULL
CD4*	NULL
T	NULL
cell	NULL
purification	NULL
.	NULL

Anti-CD4-613	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
,	NULL
anti-CD8-FITC	NULL
,	NULL
CD44-PE	NULL
,	NULL
B220-FITC	NULL
,	NULL
anti-TCRaf	NULL
(	NULL
H57	NULL
)	NULL
-FITC	NULL
(	NULL
all	NULL
from	NULL
PharMingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
were	NULL
used	NULL
for	NULL
flow	NULL
cytometry	NULL
.	NULL

Anti-IL-2	NULL
and	NULL
anti-IL-2-biotin	NULL
Abs	NULL
(	NULL
PharMingen	NULL
)	NULL
were	NULL
used	NULL
for	NULL
the	NULL
ELISA	NULL
.	NULL

Sulfate	NULL
polystyrene	NULL
latex	NULL
microspheres	NULL
of	NULL
5	NULL
um	NULL
+	NULL
0.1	NULL
pum	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
cdk	NULL
,	NULL
cyclin-dependent	NULL
kinase	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
LNT	NULL
,	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
.	NULL

INHIBITION	NULL
OF	NULL
EARLY	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
BY	NULL
CTLA-4	NULL
mean	NULL
diameters	NULL
were	NULL
obtained	NULL
from	NULL
Interfacial	NULL
Dynamics	NULL
(	NULL
Portland	NULL
,	NULL
OR	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Sandoz	NULL
(	NULL
East	NULL
Hanover	NULL
,	NULL
NJ	NULL
)	NULL
.	NULL

RNA	NULL
preparation	NULL
and	NULL
quantitative	NULL
RT-PCR	NULL
RNA	NULL
samples	NULL
were	NULL
obtained	NULL
from	NULL
single-cell	NULL
suspensions	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
cells/sample	NULL
)	NULL
using	NULL
guanidinium	NULL
isothiocyanate	NULL
by	NULL
standard	NULL
techniques	NULL
.	NULL

A	NULL
total	NULL
of	NULL
1-4	NULL
pg	NULL
of	NULL
RNA	NULL
was	NULL
reverse-transcribed	NULL
using	NULL
Superscript	NULL
II	NULL
Reverse	NULL
Transcriptase	NULL
(	NULL
Life	NULL
Technologies/BRL	NULL
)	NULL
and	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
primer	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

The	NULL
cDNA	NULL
equivalent	NULL
of	NULL
5	NULL
ng	NULL
RNA	NULL
was	NULL
amplified	NULL
containing	NULL
250	NULL
mM	NULL
each	NULL
of	NULL
dNTP	NULL
(	NULL
dATP	NULL
,	NULL
dCTP	NULL
,	NULL
dGTP	NULL
,	NULL
dTTP	NULL
)	NULL
,	NULL
200	NULL
nM	NULL
specific	NULL
oligo	NULL
primers	NULL
(	NULL
Cancer	NULL
Research	NULL
Lab	NULL
,	NULL
University	NULL
of	NULL
California	NULL
Berkeley	NULL
)	NULL
and	NULL
1	NULL
U	NULL
Taq	NULL
Polymerase	NULL
(	NULL
AmpliTaq	NULL
;	NULL
Per-kin-Elmer/Cetus	NULL
,	NULL
Norwalk	NULL
,	NULL
CT	NULL
)	NULL
for	NULL
35	NULL
cycles	NULL
:	NULL
1	NULL
min	NULL
at	NULL
95°C	NULL
,	NULL
2	NULL
min	NULL
at	NULL
60°C	NULL
,	NULL
and	NULL
2	NULL
min	NULL
at	NULL
72°C	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
run	NULL
on	NULL
a	NULL
1.2	NULL
%	NULL
agarose	NULL
gel	NULL
by	NULL
electrophoresis	NULL
.	NULL

Amplification	NULL
products	NULL
were	NULL
analyzed	NULL
for	NULL
specificity	NULL
by	NULL
restriction	NULL
analysis	NULL
with	NULL
two	NULL
enzymes	NULL
indicative	NULL
of	NULL
the	NULL
expected	NULL
amplified	NULL
sequence	NULL
.	NULL

The	NULL
primer	NULL
sequences	NULL
specific	NULL
for	NULL
B-actin	NULL
and	NULL
IL-2	NULL
were	NULL
used	NULL
as	NULL
described	NULL
(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
competitor	NULL
fragments	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
plasmid	NULL
pMCQ	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
T.	NULL
Blankenstein	NULL
(	NULL
Max-Delbriick	NULL
Center	NULL
for	NULL
Molecular	NULL
Medicine	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
)	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Each	NULL
cDNA	NULL
ali-quot	NULL
was	NULL
adjusted	NULL
to	NULL
contain	NULL
an	NULL
equal	NULL
amount	NULL
of	NULL
B-actin	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
mole-cules	NULL
)	NULL
based	NULL
on	NULL
a	NULL
comparison	NULL
to	NULL
the	NULL
competitor	NULL
DNA	NULL
.	NULL

Amplification	NULL
with	NULL
IL-2-specific	NULL
primers	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
serial	NULL
dilutions	NULL
(	NULL
1:2	NULL
)	NULL
of	NULL
competitor	NULL
fragments	NULL
,	NULL
to	NULL
estimate	NULL
the	NULL
amount	NULL
required	NULL
to	NULL
achieve	NULL
equal	NULL
band	NULL
intensities	NULL
for	NULL
both	NULL
fragments	NULL
(	NULL
52	NULL
,	NULL
53	NULL
)	NULL
.	NULL

For	NULL
mRNA	NULL
stabilization	NULL
experiments	NULL
,	NULL
the	NULL
cDNA	NULL
was	NULL
normalized	NULL
by	NULL
calculation	NULL
to	NULL
the	NULL
same	NULL
amounts	NULL
of	NULL
B-actin	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
molecules	NULL
)	NULL
,	NULL
and	NULL
values	NULL
were	NULL
plotted	NULL
as	NULL
molecules	NULL
of	NULL
competitor	NULL
fragment	NULL
.	NULL

Preparation	NULL
of	NULL
CD4¢	NULL
T	NULL
lymphocytes	NULL
Single	NULL
cell	NULL
suspensions	NULL
were	NULL
prepared	NULL
from	NULL
the	NULL
lymph	NULL
node	NULL
cells	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
by	NULL
treatment	NULL
with	NULL
complement	NULL
,	NULL
anti-MHC	NULL
class	NULL
II	NULL
Abs	NULL
,	NULL
and	NULL
anti-CD8	NULL
Abs	NULL
,	NULL
as	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Typically	NULL
,	NULL
the	NULL
cell	NULL
preparations	NULL
were	NULL
>	NULL
96	NULL
%	NULL
CD4*	NULL
cells	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
by	NULL
cell	NULL
sorting	NULL
from	NULL
CD4*	NULL
cells	NULL
enriched	NULL
spleen	NULL
and	NULL
lymph	NULL
node	NULL
cells	NULL
using	NULL
an	NULL
ELITE	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

The	NULL
recovered	NULL
cell	NULL
population	NULL
was	NULL
>	NULL
99	NULL
%	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Activation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
Latex	NULL
microspheres	NULL
were	NULL
coated	NULL
as	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1	NULL
X	NULL
10	NULL
``	NULL
beads/ml	NULL
were	NULL
suspended	NULL
in	NULL
PBS	NULL
with	NULL
the	NULL
indicated	NULL
Abs	NULL
and	NULL
incubated	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
followed	NULL
by	NULL
washing	NULL
with	NULL
PBS	NULL
and	NULL
blocking	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Anti-CD3	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
,	NULL
anti-CD28	NULL
(	NULL
1.2	NULL
ug/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
and	NULL
anti-CTLA-4	NULL
(	NULL
2	NULL
pg/ml	NULL
!	NULL
)	NULL

were	NULL
added	NULL
and	NULL
control	NULL
hamster	NULL
anti-Vy3	NULL
(	NULL
536	NULL
)	NULL
Ab	NULL
was	NULL
added	NULL
to	NULL
maintain	NULL
a	NULL
constant	NULL
total	NULL
Ab	NULL
concentration	NULL
of	NULL
5	NULL
ug/ml	NULL
.	NULL

T	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
a	NULL
ratio	NULL
of	NULL
1:1	NULL
with	NULL
beads	NULL
in	NULL
96-well	NULL
plates	NULL
.	NULL

Cultures	NULL
were	NULL
incubated	NULL
for	NULL
indicated	NULL
lengths	NULL
of	NULL
time	NULL
and	NULL
pulsed	NULL
with	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
1	NULL
Ci	NULL
)	NULL
12	NULL
h	NULL
before	NULL
harvesting	NULL
.	NULL

Plates	NULL
were	NULL
harvested	NULL
to	NULL
glass	NULL
filter	NULL
mats	NULL
and	NULL
°H	NULL
incorporation	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
gas-phase	NULL
counter	NULL
(	NULL
Packard	NULL
,	NULL
Me-riden	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

For	NULL
all	NULL
of	NULL
the	NULL
experiments	NULL
that	NULL
required	NULL
the	NULL
cells	NULL
to	NULL
be	NULL
collected	NULL
at	NULL
early	NULL
time	NULL
points	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
proliferation	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
duplicate	NULL
to	NULL
ensure	NULL
that	NULL
beads	NULL
performed	NULL
appropriately	NULL
.	NULL

Ab-coated	NULL
beads	NULL
were	NULL
also	NULL
tested	NULL
using	NULL
CD4*	NULL
CTLA-4~'~	NULL
T	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
of	NULL
anti-CTLA-4	NULL
Ab	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
proliferative	NULL
response	NULL
to	NULL
CD3/28	NULL
cross-linking	NULL
in	NULL
these	NULL
experiments	NULL
.	NULL

Luciferase	NULL
assay	NULL
Luciferase	NULL
assays	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
luminometer	NULL
manufacturer	NULL
's	NULL
instructions	NULL
,	NULL
as	NULL
described	NULL
(	NULL
Luciferase	NULL
Assay	NULL
Guide	NULL
Book	NULL
,	NULL
Analytical	NULL
Luminescence	NULL
Laboratory	NULL
,	NULL
1992	NULL
;	NULL
Ref	NULL
.	NULL

54	NULL
)	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
lysing	NULL
the	NULL
cell	NULL
pellets	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
cell/sample	NULL
)	NULL
in	NULL
lysis	NULL
buffer	NULL
and	NULL
,	NULL
after	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
were	NULL
centrifuged	NULL
for	NULL
5	NULL
min	NULL
at	NULL
1000	NULL
X	NULL
g	NULL
to	NULL
remove	NULL
cell	NULL
debris	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
divided	NULL
into	NULL
three	NULL
100-pl	NULL
aliquots	NULL
to	NULL
which	NULL
0.2	NULL
mM	NULL
enzyme	NULL
coenzyme	NULL
A	NULL
,	NULL
300	NULL
pil	NULL
luciferase	NULL
assay	NULL
buffer	NULL
,	NULL
and	NULL
100	NULL
pl	NULL
1	NULL
mM	NULL
luciferin	NULL
substrate	NULL
were	NULL
added	NULL
.	NULL

The	NULL
luciferase	NULL
activity	NULL
was	NULL
assayed	NULL
using	NULL
the	NULL
Dynatech	NULL
(	NULL
Chantilly	NULL
,	NULL
VA	NULL
)	NULL
luminometer	NULL
on	NULL
integrated	NULL
flash	NULL
mode	NULL
.	NULL

Values	NULL
presented	NULL
are	NULL
relative	NULL
light	NULL
units	NULL
gained	NULL
by	NULL
integrating	NULL
over	NULL
20-s	NULL
minus	NULL
light	NULL
units	NULL
of	NULL
wells	NULL
with	NULL
buffer	NULL
plus	NULL
luciferin	NULL
alone	NULL
.	NULL

Measurement	NULL
of	NULL
lymphokine	NULL
production	NULL
IL-2	NULL
in	NULL
cell	NULL
supernatants	NULL
was	NULL
detected	NULL
by	NULL
ELISA	NULL
,	NULL
as	NULL
described	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
standard	NULL
curve	NULL
was	NULL
generated	NULL
using	NULL
rIL-2	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
detection	NULL
was	NULL
2	NULL
ng/ml	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Western	NULL
blot	NULL
analysis	NULL
CD4*	NULL
primary	NULL
T	NULL
lymphocytes	NULL
cells	NULL
were	NULL
pelleted	NULL
and	NULL
lysed	NULL
in	NULL
Triton	NULL
buffer	NULL
(	NULL
150	NULL
mM	NULL
NaC	NULL
]	NULL
,	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
PMSF	NULL
)	NULL
for	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
lysates	NULL
were	NULL
spun	NULL
down	NULL
at	NULL
4°C	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
resulting	NULL
supernatants	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
protein	NULL
concentration	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Forty	NULL
micro-grams	NULL
of	NULL
each	NULL
sample	NULL
was	NULL
loaded	NULL
onto	NULL
a	NULL
12	NULL
%	NULL
SDS-polyacrylamide	NULL
gel	NULL
and	NULL
resolved	NULL
electrophoretically	NULL
.	NULL

The	NULL
gel	NULL
was	NULL
then	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
and	NULL
stained	NULL
with	NULL
Ponseau	NULL
S	NULL
to	NULL
ensure	NULL
equivalent	NULL
loading	NULL
and	NULL
transfer	NULL
.	NULL

Western	NULL
blot	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
1	NULL
pg/ml	NULL
of	NULL
anti-cdk4	NULL
,	NULL
anti-cdk6	NULL
,	NULL
anti-cyclin	NULL
D3	NULL
,	NULL
anti-p27	NULL
Abs	NULL
(	NULL
all	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnol-ogy	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
or	NULL
1	NULL
pug	NULL
of	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
anti-p19	NULL
Ab	NULL
(	NULL
55	NULL
)	NULL
.	NULL

The	NULL
bound	NULL
Ab	NULL
was	NULL
detected	NULL
by	NULL
the	NULL
appropriate	NULL
HRP-conjugated	NULL
secondary	NULL
Ab	NULL
.	NULL

Blots	NULL
were	NULL
developed	NULL
with	NULL
the	NULL
Renaissance	NULL
Chemiluminescence	NULL
Reagent	NULL
(	NULL
Dupont	NULL
NEN	NULL
,	NULL
Wilmington	NULL
,	NULL
DE	NULL
)	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assays	NULL
Nuclear	NULL
extracts	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
reported	NULL
(	NULL
54	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
kinetics	NULL
of	NULL
cyclin	NULL
D3	NULL
expression	NULL
reported	NULL
using	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
56	NULL
,	NULL
57	NULL
)	NULL
,	NULL
the	NULL
extracts	NULL
were	NULL
prepared	NULL
22	NULL
h	NULL
after	NULL
activation	NULL
.	NULL

The	NULL
oligonucleotides	NULL
for	NULL
NF-AT	NULL
(	NULL
GTTGCCCAAAGAGGAAAATTTGTTTCATACAG	NULL
)	NULL
and	NULL
AP-1	NULL
(	NULL
CGCTTGATGACTCAGCCGGAA	NULL
)	NULL
were	NULL
synthesized	NULL
in	NULL
the	NULL
Microchem-ical	NULL
Facility	NULL
of	NULL
the	NULL
Cancer	NULL
Research	NULL
Laboratory	NULL
(	NULL
University	NULL
of	NULL
California	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
of	NULL
the	NULL
*°P-labeled	NULL
probe	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
with	NULL
4	NULL
pg	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
performed	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
radioactive	NULL
probe	NULL
was	NULL
completely	NULL
blocked	NULL
by	NULL
the	NULL
A	NULL
Control	NULL
«	NULL
CD3	NULL
FIGURE	NULL
1	NULL
.	NULL

CTLA-4	NULL
engagement	NULL
inhibits	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
in	NULL
CD4*	NULL
T	NULL
cells	NULL
upon	NULL
activation	NULL
.	NULL

A	NULL
,	NULL
Resting	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
,	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
,	NULL
anti-CD3	NULL
«	NULL
CD3	NULL
and	NULL
anti-€CD28	NULL
plus	NULL
anti-CTLA-4	NULL
,	NULL
or	NULL
a	NULL
control	NULL
Ab	NULL
«	NULL
CD28	NULL
and	NULL
analyzed	NULL
for	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
by	NULL
quantitative	NULL
PCR	NULL
at	NULL
7-h	NULL
postactivation	NULL
.	NULL

Leff	NULL
,	NULL
All	NULL
cDNAs	NULL
were	NULL
equalized	NULL
to	NULL
5	NULL
X	NULL
10°	NULL
molecules	NULL
of	NULL
B-actin	NULL
by	NULL
coamplification	NULL
of	NULL
constant	NULL
amounts	NULL
of	NULL
cDNA	NULL
and	NULL
23328	NULL
2-fold	NULL
diluted	NULL
control	NULL
fragments	NULL
.	NULL

The	NULL
arrow	NULL
indi-	NULL
cates	NULL
the	NULL
amplified	NULL
competitor	NULL
fragment	NULL
.	NULL

Right	NULL
,	NULL
Constant	NULL
amounts	NULL
of	NULL
the	NULL
calibrated	NULL
cDNAs	NULL
were	NULL
B	NULL
coamplified	NULL
with	NULL
specific	NULL
primers	NULL
for	NULL
IL-2	NULL
in	NULL
the	NULL
5815	NULL
addition	NULL
of	NULL
20-fold	NULL
excess	NULL
nonradiolabeled	NULL
probe	NULL
,	NULL
whereas	NULL
addition	NULL
of	NULL
a	NULL
sequence	NULL
from	NULL
an	NULL
irrelevant	NULL
site	NULL
(	NULL
NBRE	NULL
)	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
radioactive	NULL
probes	NULL
.	NULL

Bound	NULL
and	NULL
unbound	NULL
probes	NULL
were	NULL
resolved	NULL
electro-phoretically	NULL
on	NULL
a	NULL
4	NULL
%	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

For	NULL
NF-AT	NULL
binding	NULL
,	NULL
the	NULL
reaction	NULL
mix	NULL
contained	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
.	NULL

For	NULL
AP-1	NULL
binding	NULL
,	NULL
reaction	NULL
mix	NULL
contains	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
100	NULL
mM	NULL
KCl	NULL
,	NULL
and	NULL
10	NULL
%	NULL
glycerol	NULL
.	NULL

Results	NULL
CTLA-4	NULL
engagement	NULL
inhibits	NULL
accumulation	NULL
of	NULL
IL-2	NULL
mRNA	NULL
in	NULL
CD4	NULL
*T	NULL
cells	NULL
CD4	NULL
*	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
(	NULL
LNT	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
Ab-coated	NULL
beads	NULL
,	NULL
and	NULL
proliferation	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
8	NULL
,	NULL
17	NULL
)	NULL
.	NULL

As	NULL
reported	NULL
(	NULL
17	NULL
)	NULL
,	NULL
CD4*	NULL
LNT	NULL
proliferation	NULL
and	NULL
IL-2	NULL
secretion	NULL
to	NULL
submitogenic	NULL
doses	NULL
of	NULL
anti-CD3	NULL
was	NULL
augmented	NULL
by	NULL
CD28-mediated	NULL
costimulation	NULL
,	NULL
and	NULL
this	NULL
response	NULL
was	NULL
inhibited	NULL
by	NULL
cross-linking	NULL
CTLA-4	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
detect	NULL
early	NULL
effects	NULL
of	NULL
CTLA-4	NULL
engagement	NULL
on	NULL
IL-2	NULL
transcription	NULL
,	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
in	NULL
CD4	NULL
*	NULL
LNT	NULL
cells	NULL
stimulated	NULL
under	NULL
these	NULL
conditions	NULL
were	NULL
assessed	NULL
by	NULL
competitive	NULL
PCR	NULL
.	NULL

Competitor	NULL
DNA	NULL
fragments	NULL
are	NULL
included	NULL
in	NULL
the	NULL
samples	NULL
,	NULL
and	NULL
the	NULL
same	NULL
primers	NULL
amplify	NULL
both	NULL
fragments	NULL
,	NULL
thus	NULL
the	NULL
amount	NULL
of	NULL
cDNA/sample	NULL
can	NULL
be	NULL
quantitated	NULL
by	NULL
B-actin	NULL
IL-2	NULL
presence	NULL
of	NULL
2-fold	NULL
serially	NULL
diluted	NULL
competitor	NULL
frag-	NULL
250000	NULL
ments	NULL
starting	NULL
with	NULL
1	NULL
X	NULL
10°	NULL
molecules	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
amplified	NULL
competitor	NULL
fragment	NULL
.	NULL

B	NULL
,	NULL
Resting	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-	NULL
é	NULL
200000	NULL
CD3	NULL
(	NULL
diamond	NULL
)	NULL
,	NULL
anti-CD3	NULL
,	NULL
and	NULL
anti-CD28	NULL
(	NULL
open	NULL
&	NULL
,	NULL
circles	NULL
)	NULL
,	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
plus	NULL
anti-	NULL
E	NULL
CTLA-4	NULL
(	NULL
filled	NULL
circles	NULL
)	NULL
,	NULL
or	NULL
a	NULL
control	NULL
Ab	NULL
(	NULL
square	NULL
)	NULL
é	NULL
and	NULL
analyzed	NULL
for	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
by	NULL
quan-	NULL
8	NULL
150000	NULL
titative	NULL
PCR	NULL
at	NULL
the	NULL
times	NULL
indicated	NULL
.	NULL

The	NULL
lower	NULL
de-	NULL
g	NULL
tection	NULL
limit	NULL
was	NULL
considered	NULL
to	NULL
be	NULL
~250	NULL
molecules	NULL
S	NULL
of	NULL
competitor	NULL
fragments	NULL
.	NULL

Each	NULL
time	NULL
point	NULL
has	NULL
been	NULL
E	NULL
100000	NULL
-I	NULL
repeated	NULL
three	NULL
to	NULL
five	NULL
times	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

3	NULL
o	NULL
2	NULL
50000	NULL
0	NULL
0	NULL
Q	NULL
i	NULL
:	NULL
I	NULL
“	NULL
.	NULL

--	NULL
-	NULL
_	NULL
Control	NULL
6	NULL
6	NULL
s	NULL
ecD3	NULL
\	NULL
~***O~~**	NULL
_	NULL
aCD3+aCD28	NULL
0	NULL
O	NULL
--	NULL
--	NULL
~	NULL
>	NULL
-	NULL
>	NULL
-	NULL
el	NULL
~~~~®	NULL
@	NULL
~~~~	NULL
_	NULL
o	NULL
CD3+0CD28+0CTLA-4	NULL
5	NULL
10	NULL
15	NULL
20	NULL
time	NULL
(	NULL
h	NULL
)	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5816	NULL
s	NULL
Microspheres	NULL
5	NULL
3	NULL
-O-	NULL
«	NULL
CD3	NULL
«	NULL
&	NULL
g	NULL
aCD3+aCD28	NULL
E	NULL
&	NULL
8	NULL
ann	NULL
@	NULL
b	NULL
ol	NULL
=	NULL
m	NULL
2	NULL
0	NULL
50	NULL
100	NULL
time	NULL
(	NULL
min	NULL
after	NULL
CsA	NULL
addition	NULL
)	NULL
FIGURE	NULL
2	NULL
.	NULL

IL-2	NULL
mRNA	NULL
decay	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
altered	NULL
by	NULL
CTLA-4	NULL
engagement	NULL
after	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
stimulation	NULL
.	NULL

Resting	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
precultured	NULL
for	NULL
4	NULL
h	NULL
with	NULL
Ab-coated	NULL
microspheres	NULL
,	NULL
as	NULL
indicated	NULL
before	NULL
CsA	NULL
addition	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
for	NULL
mRNA	NULL
assay	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
after	NULL
the	NULL
CsA	NULL
addition	NULL
(	NULL
time	NULL
zero	NULL
)	NULL
.	NULL

Quantitative	NULL
PCR	NULL
was	NULL
performed	NULL
for	NULL
IL-2	NULL
mRNA	NULL
.	NULL

All	NULL
cDNAs	NULL
were	NULL
normalized	NULL
to	NULL
5	NULL
X	NULL
10°	NULL
molecules	NULL
of	NULL
B-actin	NULL
.	NULL

Values	NULL
are	NULL
expressed	NULL
as	NULL
log	NULL
,	NULL
,	NULL
molecules	NULL
of	NULL
competitor	NULL
fragments	NULL
.	NULL

One	NULL
of	NULL
two	NULL
similar	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

comparison	NULL
to	NULL
known	NULL
amounts	NULL
of	NULL
the	NULL
competitor	NULL
fragment	NULL
over	NULL
a	NULL
series	NULL
of	NULL
dilutions	NULL
(	NULL
52	NULL
,	NULL
53	NULL
)	NULL
.	NULL

The	NULL
product	NULL
from	NULL
the	NULL
competitor	NULL
fragment	NULL
can	NULL
be	NULL
distinguished	NULL
from	NULL
the	NULL
endogenous	NULL
IL-2	NULL
mRNA	NULL
by	NULL
gel	NULL
electrophoresis	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
by	NULL
digestion	NULL
with	NULL
unique	NULL
restriction	NULL
enzymes	NULL
.	NULL

In	NULL
the	NULL
first	NULL
step	NULL
,	NULL
the	NULL
cDNA	NULL
concentrations	NULL
are	NULL
normalized	NULL
using	NULL
B-actin	NULL
as	NULL
a	NULL
standard	NULL
.	NULL

The	NULL
cDNA	NULL
concentration	NULL
that	NULL
was	NULL
required	NULL
to	NULL
achieve	NULL
equal	NULL
band	NULL
intensities	NULL
for	NULL
both	NULL
the	NULL
cDNA	NULL
and	NULL
the	NULL
competitor	NULL
fragments	NULL
was	NULL
determined	NULL
by	NULL
coamplifying	NULL
serial	NULL
dilutions	NULL
of	NULL
the	NULL
competitor	NULL
fragment	NULL
and	NULL
constant	NULL
amounts	NULL
of	NULL
cDNA	NULL
,	NULL
thus	NULL
ensuring	NULL
that	NULL
equal	NULL
amounts	NULL
of	NULL
cDNA	NULL
were	NULL
compared	NULL
in	NULL
subsequent	NULL
experiments	NULL
.	NULL

In	NULL
the	NULL
second	NULL
step	NULL
,	NULL
the	NULL
calibrated	NULL
cDNAs	NULL
were	NULL
used	NULL
for	NULL
IL-2	NULL
cDNA	NULL
amplification	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
serial	NULL
dilutions	NULL
of	NULL
competitor	NULL
fragments	NULL
containing	NULL
IL-2	NULL
primers-specific	NULL
sequences	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
beads	NULL
coated	NULL
with	NULL
anti-CD3	NULL
alone	NULL
accumulated	NULL
very	NULL
little	NULL
IL-2	NULL
mRNA	NULL
.	NULL

Stimulation	NULL
with	NULL
anti-CD3	NULL
plus	NULL
anti-CD28-coated	NULL
beads	NULL
resulted	NULL
in	NULL
rapid	NULL
accumulation	NULL
of	NULL
IL-2	NULL
mRNA	NULL
at	NULL
levels	NULL
up	NULL
to	NULL
100-fold	NULL
higher	NULL
than	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
alone	NULL
.	NULL

This	NULL
occurred	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

Levels	NULL
peaked	NULL
at	NULL
10	NULL
h	NULL
,	NULL
and	NULL
then	NULL
declined	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
when	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
by	NULL
anti-CD3	NULL
plus	NULL
CD28	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CTLA-4	NULL
,	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
was	NULL
greatly	NULL
inhibited	NULL
over	NULL
the	NULL
entire	NULL
time	NULL
course	NULL
.	NULL

Similar	NULL
to	NULL
a	NULL
recent	NULL
report	NULL
using	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
18	NULL
)	NULL
,	NULL
the	NULL
early	NULL
appearance	NULL
of	NULL
IL-2	NULL
mRNA	NULL
was	NULL
blocked	NULL
by	NULL
anti-CTLA-4	NULL
cross-linking	NULL
,	NULL
and	NULL
,	NULL
after	NULL
more	NULL
than	NULL
10	NULL
h	NULL
,	NULL
reached	NULL
levels	NULL
only	NULL
<	NULL
1	NULL
%	NULL
of	NULL
those	NULL
in	NULL
control	NULL
co-stimulated	NULL
cultures	NULL
.	NULL

CTLA-4	NULL
cross-linking	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
stabilization	NULL
of	NULL
IL-2	NULL
mRNA	NULL
by	NULL
CD28	NULL
One	NULL
effect	NULL
of	NULL
CD28	NULL
costimulation	NULL
is	NULL
to	NULL
stabilize	NULL
the	NULL
mRNA	NULL
of	NULL
a	NULL
number	NULL
of	NULL
cytokine	NULL
genes	NULL
,	NULL
including	NULL
IL-2	NULL
,	NULL
all	NULL
of	NULL
which	NULL
have	NULL
an	NULL
AU-rich	NULL
sequence	NULL
in	NULL
the	NULL
3	NULL
'	NULL
noncoding	NULL
region	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
CTLA-4	NULL
ligation	NULL
on	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
was	NULL
a	NULL
result	NULL
of	NULL
mRNA	NULL
de-stabilization	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

To	NULL
do	NULL
this	NULL
,	NULL
CsA	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
4	NULL
h	NULL
after	NULL
T	NULL
cell	NULL
stimulation	NULL
with	NULL
Ab-coated	NULL
beads	NULL
,	NULL
and	NULL
competitive	NULL
RT-PCR	NULL
was	NULL
used	NULL
to	NULL
follow	NULL
the	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
only	NULL
minimal	NULL
amounts	NULL
of	NULL
IL-2	NULL
mRNA	NULL
were	NULL
produced	NULL
in	NULL
anti-CD3-stimulated	NULL
cells	NULL
,	NULL
and	NULL
levels	NULL
began	NULL
to	NULL
decrease	NULL
rapidly	NULL
70	NULL
min	NULL
after	NULL
CsA	NULL
addition	NULL
.	NULL

These	NULL
results	NULL
are	NULL
comparable	NULL
to	NULL
that	NULL
re	NULL
INHIBITION	NULL
OF	NULL
EARLY	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
BY	NULL
CTLA-4	NULL
80	NULL
O	NULL
I	NULL
+	NULL
nmymcsa	NULL
El	NULL
60	NULL
RLU	NULL
404	NULL
Microspheres	NULL
1	NULL
.	NULL

Control	NULL
2	NULL
.	NULL

«	NULL
CD3	NULL
T	NULL
3	NULL
.	NULL

«	NULL
CD3+aCD028	NULL
4	NULL
.	NULL

«	NULL
CD8+0CD28+aCTLA-4	NULL
'|	NULL
'	NULL
5.	NULL
eCD3+aCTLA-4	NULL
nd	NULL
L.	NULL
1	NULL
3	NULL
4	NULL
5	NULL
FIGURE	NULL
3	NULL
.	NULL

Luciferase	NULL
induction	NULL
is	NULL
inhibited	NULL
by	NULL
CTLA-4	NULL
cross-linking	NULL
in	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
IL-2P-luc	NULL
transgenic	NULL
mouse	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
from	NULL
IL-2P-luc	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
Ab-coated	NULL
microspheres	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
at	NULL
4.5	NULL
h	NULL
,	NULL
lysed	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
assayed	NULL
for	NULL
luciferase	NULL
activity	NULL
.	NULL

Each	NULL
point	NULL
represents	NULL
triplicates	NULL
of	NULL
1	NULL
X	NULL
10°	NULL
cells	NULL
.	NULL

All	NULL
results	NULL
are	NULL
represented	NULL
as	NULL
means	NULL
+	NULL
SD	NULL
.	NULL

This	NULL
is	NULL
representative	NULL
data	NULL
from	NULL
three	NULL
experiments	NULL
.	NULL

20	NULL
&	NULL
_	NULL
[	NULL
_i	NULL
ported	NULL
for	NULL
a	NULL
Th1	NULL
clone	NULL
stimulated	NULL
with	NULL
plate-bound	NULL
anti-CD3	NULL
(	NULL
38	NULL
)	NULL
.	NULL

In	NULL
cultures	NULL
activated	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
,	NULL
there	NULL
was	NULL
a	NULL
500-fold	NULL
increase	NULL
in	NULL
the	NULL
absolute	NULL
amount	NULL
of	NULL
IL-2	NULL
mRNA	NULL
,	NULL
and	NULL
only	NULL
a	NULL
minor	NULL
decay	NULL
of	NULL
IL-2	NULL
mRNA	NULL
was	NULL
detected	NULL
following	NULL
the	NULL
addition	NULL
of	NULL
CsA	NULL
.	NULL

When	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CTLA-4	NULL
in	NULL
conjunction	NULL
with	NULL
anti-CD3/28	NULL
,	NULL
the	NULL
absolute	NULL
amount	NULL
of	NULL
IL-2	NULL
mRNA	NULL
was	NULL
<	NULL
1/50th	NULL
of	NULL
that	NULL
observed	NULL
with	NULL
CD3	NULL
plus	NULL
CD28	NULL
cross-linking	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
slope	NULL
of	NULL
the	NULL
curves	NULL
of	NULL
the	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
appears	NULL
similar	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
rates	NULL
of	NULL
decay	NULL
are	NULL
un-changed	NULL
.	NULL

Thus	NULL
,	NULL
CTLA-4	NULL
engagement	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
accelerate	NULL
the	NULL
decay	NULL
of	NULL
IL-2	NULL
mRNA	NULL
and	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
reverse	NULL
the	NULL
stabilization	NULL
mediated	NULL
by	NULL
CD28	NULL
cross-linking	NULL
.	NULL

Transcription	NULL
initiation	NULL
of	NULL
IL-2	NULL
in	NULL
freshly	NULL
isolated	NULL
CD4	NULL
``	NULL
T	NULL
cells	NULL
is	NULL
enhanced	NULL
by	NULL
CD28	NULL
and	NULL
inhibited	NULL
by	NULL
CTLA-4	NULL
engagement	NULL
To	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
CTLA-4	NULL
ligation	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
we	NULL
used	NULL
a	NULL
transgenic	NULL
mouse	NULL
bearing	NULL
a	NULL
luciferase	NULL
reporter	NULL
gene	NULL
under	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
enhancer	NULL
(	NULL
IL-2P-luc	NULL
)	NULL
.	NULL

The	NULL
transgene	NULL
behaved	NULL
similarly	NULL
to	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
,	NULL
as	NULL
determined	NULL
by	NULL
examining	NULL
the	NULL
effects	NULL
of	NULL
PMA/	NULL
ionomycin	NULL
and	NULL
anti-CD3/PMA	NULL
on	NULL
luciferase	NULL
activity	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
these	NULL
mice	NULL
.	NULL

These	NULL
stimuli	NULL
led	NULL
to	NULL
the	NULL
rapid	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
,	NULL
and	NULL
the	NULL
effect	NULL
was	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Proliferation	NULL
and	NULL
IL-2	NULL
production	NULL
by	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
IL-2P-luc	NULL
transgenic	NULL
mice	NULL
and	NULL
control	NULL
mice	NULL
were	NULL
similar	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
transgenic	NULL
T	NULL
cells	NULL
behaved	NULL
normally	NULL
in	NULL
response	NULL
to	NULL
polyclonal	NULL
stimulation	NULL
.	NULL

CD4	NULL
*	NULL
lymph	NULL
node	NULL
T	NULL
cells	NULL
from	NULL
IL-2P-luc	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
various	NULL
combinations	NULL
of	NULL
anti-CD3-	NULL
,	NULL
anti-CD28-	NULL
,	NULL
and	NULL
anti-CTLA-4-coated	NULL
beads	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
assayed	NULL
after	NULL
4.5	NULL
h.	NULL
As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
minimal	NULL
luciferase	NULL
activity	NULL
was	NULL
induced	NULL
by	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
only	NULL
,	NULL
but	NULL
this	NULL
was	NULL
enhanced	NULL
>	NULL
60-fold	NULL
by	NULL
CD28	NULL
costimulation	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
data	NULL
obtained	NULL
by	NULL
competitive	NULL
PCR	NULL
.	NULL

As	NULL
with	NULL
endogenous	NULL
IL-2	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
luciferase	NULL
activity	NULL
by	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
was	NULL
largely	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Cross-linking	NULL
CTLA-4	NULL
during	NULL
stimulation	NULL
resulted	NULL
in	NULL
an	NULL
almost	NULL
complete	NULL
(	NULL
90	NULL
%	NULL
)	NULL
inhibition	NULL
of	NULL
luciferase	NULL
production	NULL
by	NULL
the	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
CTLA-4	NULL
inhibits	NULL
IL-2	NULL
production	NULL
by	NULL
altering	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
that	NULL
this	NULL
occurs	NULL
very	NULL
early	NULL
after	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
CTLA-4	NULL
engagement	NULL
inhibits	NULL
the	NULL
accumulation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-AT	NULL
,	NULL
but	NULL
not	NULL
AP-1	NULL
in	NULL
the	NULL
nuclei	NULL
of	NULL
activated	NULL
CD4*	NULL
T	NULL
cells	NULL
Five	NULL
NF-AT	NULL
sites	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
full	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

58	NULL
)	NULL
,	NULL
four	NULL
of	NULL
which	NULL
bind	NULL
AP-1	NULL
in	NULL
association	NULL
with	NULL
NF-AT	NULL
.	NULL

Upon	NULL
activation	NULL
,	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
translocate	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
nucleus	NULL
.	NULL

Gel	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
to	NULL
assess	NULL
the	NULL
affects	NULL
of	NULL
CTLA-4	NULL
engagement	NULL
on	NULL
the	NULL
nuclear	NULL
accumulation	NULL
of	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
alone	NULL
increased	NULL
the	NULL
accumulation	NULL
of	NULL
NF-AT	NULL
in	NULL
the	NULL
nucleus	NULL
over	NULL
the	NULL
basal	NULL
levels	NULL
,	NULL
which	NULL
was	NULL
further	NULL
augmented	NULL
upon	NULL
coligation	NULL
of	NULL
CD28	NULL
.	NULL

This	NULL
increase	NULL
paralled	NULL
enhancement	NULL
of	NULL
IL-2	NULL
mRNA	NULL
transcription	NULL
initiation	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
IL-2	NULL
mRNA	NULL
accumulation	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
and	NULL
ultimately	NULL
,	NULL
IL-2	NULL
production	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
,	NULL
and	NULL
Ref	NULL
.	NULL

17	NULL
)	NULL
.	NULL

Coligation	NULL
of	NULL
CTLA-4	NULL
in	NULL
conjunction	NULL
with	NULL
anti-€CD3/28	NULL
inhibited	NULL
NF-AT	NULL
translocation	NULL
to	NULL
levels	NULL
similar	NULL
to	NULL
those	NULL
observed	NULL
when	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
NF-AT	NULL
was	NULL
CsA-sensitive	NULL
,	NULL
regardless	NULL
of	NULL
the	NULL
stimulation	NULL
conditions	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Since	NULL
only	NULL
the	NULL
translocation	NULL
of	NULL
the	NULL
factor	NULL
to	NULL
the	NULL
nucleus	NULL
is	NULL
shown	NULL
to	NULL
be	NULL
CsA-sensitive	NULL
(	NULL
59	NULL
)	NULL
,	NULL
only	NULL
NF-AT	NULL
that	NULL
had	NULL
translocated	NULL
from	NULL
the	NULL
cytoplasm	NULL
to	NULL
the	NULL
nuclear	NULL
extracts	NULL
was	NULL
measured	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
obvious	NULL
changes	NULL
in	NULL
the	NULL
AP-1	NULL
translocation	NULL
to	NULL
the	NULL
nuclear	NULL
fraction	NULL
upon	NULL
CTLA-4	NULL
engagement	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
these	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Levels	NULL
of	NULL
the	NULL
Spl	NULL
family	NULL
binding	NULL
to	NULL
the	NULL
GT-box	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
were	NULL
also	NULL
unaltered	NULL
under	NULL
all	NULL
culture	NULL
conditions	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CTLA-4	NULL
cross-linking	NULL
and	NULL
expression	NULL
of	NULL
cyclin	NULL
D3	NULL
,	NULL
cdk4	NULL
,	NULL
cdk6	NULL
,	NULL
p27	NULL
,	NULL
and	NULL
p19	NULL
Entry	NULL
into	NULL
the	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
is	NULL
regulated	NULL
by	NULL
complex	NULL
interactions	NULL
between	NULL
cyclin/cdks	NULL
and	NULL
cell	NULL
cycle	NULL
inhibitors	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

41	NULL
)	NULL
.	NULL

Initial	NULL
activation	NULL
of	NULL
cyclin	NULL
D2/3	NULL
complexed	NULL
to	NULL
cdk4/6	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
cyclin	NULL
E/cdk2	NULL
activity	NULL
are	NULL
required	NULL
for	NULL
the	NULL
entry	NULL
into	NULL
S	NULL
phase	NULL
.	NULL

The	NULL
p16	NULL
family	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
inhibitors	NULL
(	NULL
p16	NULL
,	NULL
p15	NULL
,	NULL
p18	NULL
,	NULL
and	NULL
p19	NULL
)	NULL
can	NULL
regulate	NULL
the	NULL
activity	NULL
of	NULL
cyclin	NULL
D/cdk4/6	NULL
,	NULL
while	NULL
p27	NULL
inhibits	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
cyclin	NULL
E/cdk2	NULL
.	NULL

Stimulation	NULL
of	NULL
resting	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
TCR	NULL
complex	NULL
results	NULL
in	NULL
transcriptional	NULL
activation	NULL
of	NULL
cyclin	NULL
D2	NULL
,	NULL
D3	NULL
,	NULL
cdk4	NULL
,	NULL
and	NULL
cdk6	NULL
,	NULL
as	NULL
well	NULL
as	NULL
degradation	NULL
of	NULL
p27	NULL
(	NULL
60	NULL
,	NULL
61	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
cdk6	NULL
,	NULL
edk4	NULL
,	NULL
and	NULL
cyclins	NULL
in	NULL
normal	NULL
T	NULL
cells	NULL
is	NULL
partially	NULL
dependent	NULL
on	NULL
IL-2	NULL
(	NULL
56	NULL
,	NULL
62	NULL
,	NULL
63	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
degradation	NULL
of	NULL
p27	NULL
is	NULL
completely	NULL
dependent	NULL
on	NULL
IL-2	NULL
(	NULL
60	NULL
,	NULL
61	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
CTLA-4	NULL
cross-linking	NULL
on	NULL
these	NULL
proteins	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
these	NULL
regulatory	NULL
elements	NULL
was	NULL
examined	NULL
in	NULL
CD4	NULL
*	NULL
LNT	NULL
cells	NULL
22	NULL
h	NULL
after	NULL
stimulation	NULL
under	NULL
various	NULL
conditions	NULL
.	NULL

As	NULL
previously	NULL
reported	NULL
with	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
56	NULL
,	NULL
57	NULL
,	NULL
64	NULL
)	NULL
,	NULL
CD3	NULL
engagement	NULL
alone	NULL
leads	NULL
to	NULL
cyclin	NULL
D3	NULL
,	NULL
edk4	NULL
,	NULL
and	NULL
edk6	NULL
protein	NULL
expression	NULL
,	NULL
which	NULL
are	NULL
barely	NULL
detectable	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

CD28	NULL
cross-linking	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-CD3	NULL
further	NULL
up-regulates	NULL
expression	NULL
of	NULL
these	NULL
G	NULL
,	NULL
kinases	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
engagement	NULL
of	NULL
CTLA-4	NULL
dramatically	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
these	NULL
kinase	NULL
components	NULL
when	NULL
cross-linked	NULL
in	NULL
conjunction	NULL
with	NULL
CD3/CD28-	NULL
and	NULL
by	NULL
CD3-ligation	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Degradation	NULL
of	NULL
the	NULL
inhibitor	NULL
p27	NULL
also	NULL
occurs	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
G	NULL
,	NULL
to	NULL
S	NULL
phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
60	NULL
)	NULL
.	NULL

p27	NULL
degradation	NULL
initiated	NULL
by	NULL
anti-CD3	NULL
stimulation	NULL
is	NULL
inhibited	NULL
by	NULL
CTLA-4	NULL
cross-link	NULL
ing	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

CTLA-4	NULL
engagement	NULL
in	NULL
conjunction	NULL
with	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
,	NULL
did	NULL
not	NULL
prevent	NULL
the	NULL
degradation	NULL
of	NULL
inhibitor	NULL
p27	NULL
induced	NULL
by	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Since	NULL
p27	NULL
degradation	NULL
is	NULL
IL-2-dependent	NULL
(	NULL
60	NULL
)	NULL
,	NULL
this	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
remaining	NULL
amounts	NULL
of	NULL
IL-2	NULL
produced	NULL
in	NULL
these	NULL
cultures	NULL
that	NULL
leads	NULL
to	NULL
its	NULL
deg-radation	NULL
.	NULL

Expression	NULL
of	NULL
p19	NULL
,	NULL
a	NULL
p16	NULL
family	NULL
member	NULL
(	NULL
55	NULL
)	NULL
,	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
any	NULL
of	NULL
the	NULL
stimulation	NULL
conditions	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

5817	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
X	NULL
to	NULL
tot	NULL
o	NULL
$	NULL
oc-	NULL
t	NULL
$	NULL
-o	NULL
$	NULL
o	NULL
-+	NULL
WoW	NULL
b4	NULL
b	NULL
|=	NULL
free	NULL
probe	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
X	NULL
to	NULL
to-	NULL
$	NULL
o	NULL
c-	NULL
to	NULL
-o	NULL
$	NULL
o	NULL
-o	NULL
+	NULL
bud	NULL
uto	NULL
“	NULL
“	NULL
u.	NULL
,	NULL
u.4	NULL
-a	NULL
m	NULL
|	NULL
``	NULL
*	NULL
free	NULL
probe	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
tot	NULL
-	NULL
$	NULL
-o	NULL
$	NULL
-	NULL
$	NULL
-o	NULL
+	NULL
C	NULL
X	NULL
thot	NULL
tout	NULL
tanh	NULL
booed	NULL
tut	NULL
baad	NULL
4	NULL
at	NULL
|	NULL
!	NULL
``	NULL

''	NULL
free	NULL
probe	NULL
FIGURE	NULL
4	NULL
.	NULL

Analysis	NULL
of	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
binding	NULL
activity	NULL
of	NULL
nuclear	NULL
extracts	NULL
from	NULL
activated	NULL
or	NULL
nonactivated	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

EMSA	NULL
of	NULL
nuclear	NULL
extracts	NULL
of	NULL
activated	NULL
or	NULL
nonactivated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
radioactive	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
NF-AT	NULL
(	NULL
4	NULL
)	NULL
,	NULL
AP-1	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
GT-box-sites	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
control	NULL
Ab	NULL
(	NULL
1	NULL
)	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
(	NULL
2	NULL
)	NULL
,	NULL
anti-CD3/anti-CD28	NULL
(	NULL
3	NULL
)	NULL
,	NULL
anti-CD3/anti-CD28/anti-CTLA-4	NULL
(	NULL
4	NULL
)	NULL
,	NULL
or	NULL
anti-CD3/anti-CTLA-4	NULL
(	NULL
5	NULL
)	NULL
.	NULL

CsA	NULL
was	NULL
added	NULL
(	NULL
+	NULL
)	NULL
at	NULL
1	NULL
ug/ml	NULL
.	NULL

For	NULL
each	NULL
assay	NULL
,	NULL
nuclear	NULL
extracts	NULL
(	NULL
4	NULL
ug	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
corresponding	NULL
*°P-labeled	NULL
probe	NULL
containing	NULL
the	NULL
NF-AT	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
4	NULL
)	NULL
,	NULL
or	NULL
the	NULL
AP-1-site	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
data	NULL
shown	NULL
is	NULL
representative	NULL
of	NULL
three	NULL
experiments	NULL
for	NULL
NF-AT	NULL
and	NULL
two	NULL
experiments	NULL
for	NULL
AP-1	NULL
.	NULL

*P-labeled	NULL
probe	NULL
control	NULL
is	NULL
designated	NULL
by	NULL
``	NULL
X	NULL
``	NULL
.	NULL

The	NULL
upper	NULL
arrows	NULL
indicate	NULL
specific	NULL
complexes	NULL
;	NULL
free	NULL
probe	NULL
is	NULL
indicated	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5818	NULL
anti-COD3	NULL
-	NULL
+0	NULL
+0	NULL
O+	NULL
+	NULL
anti-CD28	NULL
-	NULL
=-	NULL
+	NULL
-o	NULL
+	NULL
anti-CTLA-4	NULL
_	NULL
-	NULL
-	NULL
0	NULL
-o	NULL
o	NULL
+	NULL
cdk6	NULL
wee	NULL
cdk4	NULL
-	NULL
emmm	NULL
we	NULL
cyclin	NULL
D3	NULL
|	NULL
-	NULL
die	NULL
|	NULL
di	NULL
@	NULL
®	NULL
O	NULL
C	NULL
p27	NULL
lee	NULL
___	NULL
@	NULL
»	NULL
pi1Q	NULL
-	NULL
|O	NULL
meno	NULL
meme	NULL
mses	NULL
FIGURE	NULL
5	NULL
.	NULL

Effect	NULL
of	NULL
CTLA-4	NULL
engagement	NULL
on	NULL
the	NULL
protein	NULL
expression	NULL
of	NULL
cyclin	NULL
D3	NULL
,	NULL
edk4	NULL
,	NULL
and	NULL
cdk6	NULL
,	NULL
p27	NULL
,	NULL
and	NULL
p19	NULL
in	NULL
resting	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
Ab-coated	NULL
microspheres	NULL
as	NULL
indicated	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
obtained	NULL
and	NULL
analyzed	NULL
by	NULL
Western	NULL
blotting	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Equivalent	NULL
protein	NULL
loading	NULL
was	NULL
confirmed	NULL
by	NULL
Ponseau	NULL
S	NULL
staining	NULL
.	NULL

The	NULL
data	NULL
is	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
for	NULL
cyclin	NULL
D3	NULL
and	NULL
edk6	NULL
and	NULL
two	NULL
experiments	NULL
for	NULL
edk4	NULL
,	NULL
p27	NULL
,	NULL
and	NULL
p19	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
CTLA-4-mediated	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
results	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
from	NULL
direct	NULL
interference	NULL
with	NULL
induction	NULL
of	NULL
proteins	NULL
that	NULL
regulate	NULL
cell	NULL
cycle	NULL
pro-gression	NULL
,	NULL
rather	NULL
than	NULL
just	NULL
by	NULL
inhibiting	NULL
the	NULL
production	NULL
of	NULL
essential	NULL
growth	NULL
factor	NULL
IL-2	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
effect	NULL
of	NULL
CTLA-4	NULL
engagement	NULL
on	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
IL-2	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
(	NULL
1-80	NULL
U/ml	NULL
)	NULL
increased	NULL
proliferation	NULL
under	NULL
all	NULL
culture	NULL
conditions	NULL
,	NULL
reaching	NULL
a	NULL
plateau	NULL
at	NULL
~10	NULL
U/ml	NULL
IL-2	NULL
.	NULL

However	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
(	NULL
10-80	NULL
U/ml	NULL
!	NULL
)	NULL

did	NULL
not	NULL
reverse	NULL
the	NULL
inhibition	NULL
of	NULL
proliferation	NULL
by	NULL
CTLA-4	NULL
.	NULL

Indeed	NULL
,	NULL
despite	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
IL-2	NULL
,	NULL
CTLA-4	NULL
engagement	NULL
resulted	NULL
in	NULL
50-80	NULL
%	NULL
inhibition	NULL
of	NULL
proliferation	NULL
.	NULL

Discussion	NULL
Here	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
mechanisms	NULL
of	NULL
CTLA-4-mediated	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

One	NULL
issue	NULL
that	NULL
these	NULL
experiments	NULL
have	NULL
addressed	NULL
is	NULL
the	NULL
stage	NULL
at	NULL
which	NULL
CTLA-4	NULL
can	NULL
operate	NULL
.	NULL

Since	NULL
CTLA-4	NULL
is	NULL
not	NULL
readily	NULL
detectable	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
,	NULL
there	NULL
has	NULL
been	NULL
a	NULL
prevailing	NULL
notion	NULL
that	NULL
CTLA-4	NULL
functions	NULL
primarily	NULL
to	NULL
terminate	NULL
ongoing	NULL
T	NULL
cell	NULL
responses	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Several	NULL
previous	NULL
reports	NULL
have	NULL
suggested	NULL
that	NULL
this	NULL
might	NULL
not	NULL
be	NULL
strictly	NULL
correct	NULL
,	NULL
and	NULL
that	NULL
CTLA-4	NULL
might	NULL
function	NULL
quite	NULL
early	NULL
.	NULL

First	NULL
,	NULL
as	NULL
discussed	NULL
previously	NULL
,	NULL
CTLA-4	NULL
mRNA	NULL
and	NULL
intracellular	NULL
protein	NULL
can	NULL
be	NULL
detected	NULL
much	NULL
earlier	NULL
than	NULL
surface	NULL
expression	NULL
.	NULL

Second	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
CTLA-4	NULL
engagement	NULL
by	NULL
Ab	NULL
can	NULL
prevent	NULL
several	NULL
early	NULL
manifestations	NULL
of	NULL
T	NULL
cell	NULL
5000	NULL
-r	NULL
INHIBITION	NULL
OF	NULL
EARLY	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
BY	NULL
CTLA-4	NULL
activation	NULL
,	NULL
including	NULL
expression	NULL
of	NULL
CD69	NULL
,	NULL
CD25	NULL
,	NULL
and	NULL
IL-2	NULL
secretion	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
CTLA-4	NULL
ligation	NULL
can	NULL
prevent	NULL
accumulation	NULL
of	NULL
detectable	NULL
amounts	NULL
of	NULL
IL-2	NULL
mRNA	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
after	NULL
stimulation	NULL
of	NULL
resting	NULL
human	NULL
T	NULL
cells	NULL
by	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
(	NULL
18	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
all	NULL
suggest	NULL
that	NULL
CTLA-4	NULL
might	NULL
act	NULL
very	NULL
early	NULL
to	NULL
regulate	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Nevertheless	NULL
,	NULL
it	NULL
remains	NULL
possible	NULL
that	NULL
CTLA-4	NULL
can	NULL
also	NULL
play	NULL
a	NULL
role	NULL
in	NULL
regulating	NULL
ongoing	NULL
immune	NULL
responses	NULL
when	NULL
CTLA-4	NULL
cell	NULL
surface	NULL
expression	NULL
is	NULL
max-imal	NULL
.	NULL

These	NULL
two	NULL
possibilities	NULL
are	NULL
not	NULL
mutually	NULL
exclusive	NULL
.	NULL

Our	NULL
results	NULL
clearly	NULL
demonstrate	NULL
that	NULL
CTLA-4	NULL
inhibits	NULL
the	NULL
anti-CD3/CD28-stimulated	NULL
accumulation	NULL
of	NULL
IL-2	NULL
mRNA	NULL
by	NULL
freshly	NULL
isolated	NULL
murine	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Further	NULL
,	NULL
this	NULL
inhibition	NULL
is	NULL
due	NULL
to	NULL
a	NULL
block	NULL
in	NULL
IL-2	NULL
gene	NULL
transcription	NULL
and	NULL
may	NULL
be	NULL
a	NULL
consequence	NULL
of	NULL
inhibition	NULL
of	NULL
the	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
NF-AT	NULL
.	NULL

An	NULL
important	NULL
consequence	NULL
of	NULL
CD28-mediated	NULL
costimulation	NULL
is	NULL
stabilization	NULL
of	NULL
mRNA	NULL
of	NULL
IL-2	NULL
and	NULL
several	NULL
other	NULL
cytokines	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
CTLA-4	NULL
ligation	NULL
does	NULL
not	NULL
lead	NULL
to	NULL
IL-2	NULL
mRNA	NULL
destabilization	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
observation	NULL
that	NULL
CTLA-4	NULL
does	NULL
not	NULL
reverse	NULL
CD28-mediated	NULL
induction	NULL
of	NULL
Bel-x	NULL
,	NULL
,	NULL
(	NULL
18	NULL
)	NULL
.	NULL

These	NULL
results	NULL
strongly	NULL
suggest	NULL
that	NULL
CTLA-4	NULL
does	NULL
not	NULL
merely	NULL
counteract	NULL
the	NULL
costimulatory	NULL
effects	NULL
of	NULL
CD28	NULL
,	NULL
but	NULL
may	NULL
act	NULL
at	NULL
different	NULL
or	NULL
additional	NULL
points	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

The	NULL
notion	NULL
that	NULL
CTLA-4	NULL
and	NULL
CD28	NULL
costimulation	NULL
may	NULL
have	NULL
independent	NULL
effects	NULL
is	NULL
further	NULL
supported	NULL
by	NULL
recent	NULL
reports	NULL
demonstrating	NULL
that	NULL
CTLA-4	NULL
can	NULL
function	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD28	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Since	NULL
CTLA-4	NULL
ligation	NULL
can	NULL
result	NULL
in	NULL
a	NULL
very	NULL
early	NULL
inhibition	NULL
of	NULL
production	NULL
of	NULL
IL-2	NULL
,	NULL
this	NULL
might	NULL
suggest	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
by	NULL
CTLA-4	NULL
ligation	NULL
might	NULL
be	NULL
attributed	NULL
entirely	NULL
to	NULL
a	NULL
lack	NULL
of	NULL
this	NULL
essential	NULL
growth	NULL
factor	NULL
(	NULL
65	NULL
)	NULL
.	NULL

However	NULL
,	NULL
our	NULL
observation	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
excess	NULL
exogenous	NULL
IL-2	NULL
failed	NULL
to	NULL
completely	NULL
restore	NULL
proliferation	NULL
suggested	NULL
that	NULL
CTLA-4	NULL
might	NULL
be	NULL
inhibiting	NULL
T	NULL
cell	NULL
proliferation	NULL
independent	NULL
of	NULL
IL-2-mediated	NULL
effects	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
and	NULL
Ref	NULL
.	NULL

8	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
found	NULL
that	NULL
CTLA-4	NULL
ligation	NULL
inhibits	NULL
the	NULL
production	NULL
of	NULL
components	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
machinery	NULL
necessary	NULL
for	NULL
progression	NULL
through	NULL
the	NULL
G/G	NULL
,	NULL
check	NULL
point	NULL
.	NULL

This	NULL
result	NULL
indicates	NULL
that	NULL
CTLA-4	NULL
can	NULL
inhibit	NULL
T	NULL
cell	NULL
proliferation	NULL
at	NULL
two	NULL
stages	NULL
,	NULL
production	NULL
of	NULL
an	NULL
essential	NULL
growth	NULL
factor	NULL
and	NULL
induction	NULL
of	NULL
critical	NULL
components	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
machinery	NULL
.	NULL

It	NULL
is	NULL
of	NULL
interest	NULL
that	NULL
CTLA-4	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
scant	NULL
amount	NULL
of	NULL
IL-2	NULL
produced	NULL
upon	NULL
cross-linking	NULL
of	NULL
CD3/CD28/CTLA-4	NULL
to	NULL
support	NULL
the	NULL
degradation	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
inhibitor	NULL
p27	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
cross-linking	NULL
CD3	NULL
,	NULL
CD28	NULL
,	NULL
and	NULL
CTLA-4	NULL
using	NULL
Ab-coated	NULL
microspheres	NULL
.	NULL

Although	NULL
the	NULL
results	NULL
clearly	NULL
demonstrate	NULL
an	NULL
inhibitory	NULL
role	NULL
for	NULL
CTLA-4	NULL
,	NULL
it	NULL
will	NULL
be	NULL
important	NULL
to	NULL
examine	NULL
the	NULL
role	NULL
of	NULL
CTLA-4	NULL
in	NULL
regulating	NULL
T	NULL
cell	NULL
responses	NULL
using	NULL
physiological	NULL
ligands	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
4000	NULL
FIGURE	NULL
6	NULL
.	NULL

IL-2	NULL
does	NULL
not	NULL
reverse	NULL
CTLA-4	NULL
mediated	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

Puri-	NULL
3000	NULL
fied	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
for	NULL
28	NULL
h	NULL
with	NULL
the	NULL
indicated	NULL
Abs	NULL
immobilized	NULL
on	NULL
microspheres	NULL
and	NULL
1-80	NULL
U/ml	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
.	NULL

Cultures	NULL
2000	NULL
were	NULL
pulsed	NULL
12	NULL
h	NULL
before	NULL
harvest	NULL
with	NULL
1	NULL
uCi	NULL
[	NULL
*HJthymidine	NULL
.	NULL

SDs	NULL
were	NULL
within	NULL
10	NULL
%	NULL
of	NULL
the	NULL
1000	NULL
mean	NULL
.	NULL

cpm	NULL
====D	NULL
--	NULL
--	NULL
-	NULL
Control	NULL
--	NULL
--	NULL
--	NULL
--	NULL
&	NULL
``	NULL
``	NULL
-	NULL
yCD3	NULL
=O	NULL
**~*	NULL
@	NULL
-~~	NULL
_	NULL
aCD3+0CD2840CTLA4	NULL
==	NULL
~~	NULL
-	NULL
eCD3+0CTLA4	NULL
U/mL	NULL
IL-2	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
that	NULL
lymphocytic	NULL
choriomeningitis	NULL
virus-specific	NULL
and	NULL
2C	NULL
TCR	NULL
transgene-expressing	NULL
naive	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
CTLA-4	NULL
'~	NULL
and	NULL
littermate	NULL
control	NULL
mice	NULL
generated	NULL
similar	NULL
peptide-specific	NULL
proliferative	NULL
responses	NULL
in	NULL
vitro	NULL
(	NULL
66	NULL
,	NULL
67	NULL
)	NULL
.	NULL

However	NULL
,	NULL
upon	NULL
restimulation	NULL
of	NULL
the	NULL
2C	NULL
TCR	NULL
*	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
CTLA-4-deficient	NULL
cells	NULL
generated	NULL
a	NULL
dramatically	NULL
greater	NULL
proliferative	NULL
response	NULL
compared	NULL
with	NULL
the	NULL
CTLA-4	NULL
wild-type	NULL
T	NULL
cells	NULL
(	NULL
67	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
proliferative	NULL
re-sponse	NULL
,	NULL
IL-2	NULL
secretion	NULL
,	NULL
and	NULL
the	NULL
up-regulation	NULL
of	NULL
CD69	NULL
and	NULL
CD25	NULL
by	NULL
naive	NULL
2C	NULL
TCR*	NULL
T	NULL
cells	NULL
stimulated	NULL
by	NULL
anti-CD3	NULL
and	NULL
B7-trans-fected	NULL
chinese	NULL
hamster	NULL
ovary	NULL
cells	NULL
were	NULL
inhibited	NULL
by	NULL
CTLA-4	NULL
cross-linking	NULL
(	NULL
7	NULL
,	NULL
68	NULL
)	NULL
.	NULL

These	NULL
seemingly	NULL
disparate	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
role	NULL
of	NULL
CTLA-4	NULL
in	NULL
regulating	NULL
T	NULL
cell	NULL
activation	NULL
may	NULL
depend	NULL
on	NULL
the	NULL
availability	NULL
of	NULL
B7	NULL
ligands	NULL
,	NULL
strength	NULL
of	NULL
the	NULL
TCR	NULL
signal	NULL
,	NULL
and	NULL
the	NULL
activational	NULL
history	NULL
of	NULL
the	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
CTLA-4	NULL
can	NULL
exert	NULL
its	NULL
inhibitory	NULL
effects	NULL
at	NULL
multiple	NULL
points	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
including	NULL
induction	NULL
of	NULL
transcription	NULL
of	NULL
an	NULL
essential	NULL
growth	NULL
factor	NULL
gene	NULL
and	NULL
interference	NULL
with	NULL
the	NULL
production	NULL
of	NULL
critical	NULL
components	NULL
required	NULL
for	NULL
cell	NULL
cycle	NULL
progression	NULL
.	NULL

The	NULL
mechanism	NULL
appears	NULL
to	NULL
be	NULL
more	NULL
complex	NULL
than	NULL
mere	NULL
reversal	NULL
of	NULL
CD28-mediated	NULL
costimulation	NULL
.	NULL

The	NULL
cyclin-dependent	NULL
kinases	NULL
cdk4	NULL
and	NULL
cdk6	NULL
are	NULL
induced	NULL
by	NULL
anti-CD3	NULL
alone	NULL
,	NULL
but	NULL
can	NULL
be	NULL
further	NULL
augmented	NULL
upon	NULL
CD28	NULL
costimulation	NULL
(	NULL
56	NULL
,	NULL
57	NULL
,	NULL
62-64	NULL
)	NULL
.	NULL

CTLA-4	NULL
engagement	NULL
can	NULL
completely	NULL
block	NULL
anti-CD3-mediated	NULL
induction	NULL
.	NULL

Finally	NULL
,	NULL
CTLA-4	NULL
ligation	NULL
inhibits	NULL
the	NULL
induction	NULL
of	NULL
cyclin	NULL
D3	NULL
,	NULL
which	NULL
appears	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
CD28	NULL
costimulation	NULL
.	NULL

It	NULL
is	NULL
clear	NULL
that	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
can	NULL
influence	NULL
the	NULL
TCR/CD3-mediated	NULL
signal	NULL
.	NULL

The	NULL
molecular	NULL
stage	NULL
at	NULL
which	NULL
this	NULL
occurs	NULL
is	NULL
un-clear	NULL
.	NULL

There	NULL
are	NULL
several	NULL
possibilities	NULL
.	NULL

It	NULL
has	NULL
been	NULL
proposed	NULL
that	NULL
CD28	NULL
mediates	NULL
a	NULL
separate	NULL
and	NULL
parallel	NULL
pathway	NULL
that	NULL
augments	NULL
IL-2	NULL
transcription	NULL
and	NULL
T	NULL
cell	NULL
responses	NULL
(	NULL
69	NULL
)	NULL
.	NULL

Another	NULL
possibility	NULL
is	NULL
that	NULL
CD28	NULL
and	NULL
TCR/CD3	NULL
signaling	NULL
intersect	NULL
distally	NULL
at	NULL
Jnk	NULL
,	NULL
thereby	NULL
augmenting	NULL
IL-2	NULL
transcription	NULL
(	NULL
70	NULL
)	NULL
.	NULL

However	NULL
,	NULL
recently	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
CD28/B7	NULL
interaction	NULL
augments	NULL
tyrosine	NULL
phosphoryla-tion	NULL
levels	NULL
of	NULL
ZAP-70	NULL
,	NULL
vav	NULL
,	NULL
and	NULL
cbl	NULL
proteins	NULL
,	NULL
indicating	NULL
that	NULL
CD28	NULL
signaling	NULL
affects	NULL
the	NULL
CD3	NULL
signaling	NULL
pathway	NULL
directly	NULL
(	NULL
Ref	NULL
.	NULL

71	NULL
,	NULL
and	NULL
Y.	NULL
Zhang	NULL
and	NULL
J.P.A	NULL
.	NULL

,	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Regardless	NULL
of	NULL
the	NULL
mechanism	NULL
,	NULL
the	NULL
results	NULL
presented	NULL
here	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
signals	NULL
mediated	NULL
by	NULL
the	NULL
TCR	NULL
,	NULL
CD28	NULL
,	NULL
and	NULL
CTLA-4	NULL
are	NULL
not	NULL
discrete	NULL
,	NULL
but	NULL
interact	NULL
in	NULL
a	NULL
complex	NULL
and	NULL
dynamic	NULL
way	NULL
to	NULL
influence	NULL
the	NULL
outcome	NULL
of	NULL
T	NULL
cell	NULL
stimulation	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Chris	NULL
Hinkel	NULL
for	NULL
generating	NULL
the	NULL
transgenic	NULL
mouse	NULL
,	NULL
Brigitte	NULL
Boitel	NULL
for	NULL
helpful	NULL
technical	NULL
advice	NULL
,	NULL
and	NULL
Joonsoo	NULL
Kang	NULL
for	NULL
critically	NULL
reading	NULL
the	NULL
manuscript	NULL
.	NULL

References	NULL
1.	NULL
van	NULL
der	NULL
Merwe	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
D.	NULL
L.	NULL
Bodian	NULL
,	NULL
S.	NULL
Daenke	NULL
,	NULL
P.	NULL
Linsley	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Davis	NULL
.	NULL

1997	NULL
.	NULL

CD80	NULL
(	NULL
B7-1	NULL
)	NULL
binds	NULL
both	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
with	NULL
a	NULL
low	NULL
affinity	NULL
and	NULL
very	NULL
fast	NULL
kinetics	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185:393	NULL
.	NULL

2	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
S.	NULL
G.	NULL
Nadler	NULL
,	NULL
J.	NULL
Bajoirath	NULL
,	NULL
R.	NULL
Peach	NULL
,	NULL
H.	NULL
T.	NULL
Leung	NULL
,	NULL
J.	NULL
Rogers	NULL
,	NULL
J.	NULL
Bradshaw	NULL
,	NULL
M.	NULL
Stebbins	NULL
,	NULL
G.	NULL
Leytze	NULL
,	NULL
W.	NULL
Brady	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

Binding	NULL
stoichiom-etry	NULL
of	NULL
the	NULL
cytotoxic	NULL
T	NULL
lymphocyte-associated	NULL
molecule-4	NULL
(	NULL
CTLA-4	NULL
)	NULL
:	NULL
a	NULL
disulfide-linked	NULL
homodimer	NULL
binds	NULL
two	NULL
CD86	NULL
molecules	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:15417	NULL
.	NULL

3	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
J.	NULL
Bradshaw	NULL
,	NULL
J.	NULL
Greene	NULL
,	NULL
R.	NULL
Peach	NULL
,	NULL
K.	NULL
L.	NULL
Bennett	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Mittler	NULL
.	NULL

1996	NULL
.	NULL

Intracellular	NULL
trafficking	NULL
of	NULL
CTLA-4	NULL
and	NULL
focal	NULL
localization	NULL
towards	NULL
sites	NULL
of	NULL
TCR	NULL
engagement	NULL
.	NULL

Immunity	NULL
4:535	NULL
.	NULL

4	NULL
.	NULL

Leung	NULL
,	NULL
H.	NULL
T.	NULL
,	NULL
J.	NULL
Bradshaw	NULL
,	NULL
J.	NULL
S.	NULL
Cleaveland	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Linsley	NULL
.	NULL

1995	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocyte-associated	NULL
molecule-4	NULL
,	NULL
a	NULL
high	NULL
avidity	NULL
receptor	NULL
for	NULL
CD80	NULL
and	NULL
CD86	NULL
,	NULL
contains	NULL
an	NULL
intracellular	NULL
localization	NULL
motif	NULL
in	NULL
its	NULL
cytoplasmic	NULL
tail	NULL
.	NULL

J.	NULL
BioL	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
:	NULL
1	NULL
.	NULL

5	NULL
.	NULL

Wu	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Guo	NULL
,	NULL
A.	NULL
Huang	NULL
,	NULL
P.	NULL
Zheng	NULL
,	NULL
and	NULL
Y.	NULL
Liu	NULL
.	NULL

1997	NULL
.	NULL

CTLA-4-B7	NULL
interaction	NULL
is	NULL
sufficient	NULL
to	NULL
costimulate	NULL
T	NULL
cell	NULL
clonal	NULL
expansion	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185:1	NULL
.	NULL

6	NULL
.	NULL

Zheng	NULL
,	NULL
P.	NULL
,	NULL
Y.	NULL
Wu	NULL
,	NULL
Y.	NULL
Guo	NULL
,	NULL
C.	NULL
Lee	NULL
,	NULL
and	NULL
Y.	NULL
Liu	NULL
.	NULL

1998	NULL
.	NULL

B7-CTLA-4	NULL
interaction	NULL
enhances	NULL
both	NULL
production	NULL
of	NULL
antitumor	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
and	NULL
resistance	NULL
to	NULL
tumor	NULL
challenge	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95:6284	NULL
.	NULL

7	NULL
.	NULL

Walunas	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
D.	NULL
J.	NULL
Lenschow	NULL
,	NULL
C.	NULL
Y.	NULL
Bakker	NULL
,	NULL
P.	NULL
S.	NULL
Linsley	NULL
,	NULL
G.	NULL
J.	NULL
Freeman	NULL
,	NULL
J.	NULL
M.	NULL
Green	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
.	NULL

1994	NULL
.	NULL

CTLA-4	NULL
can	NULL
function	NULL
as	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Immunity	NULL
1:405	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

5819	NULL
.	NULL

Krummel	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1995	NULL
.	NULL

CD28	NULL
and	NULL
CTLA-4	NULL
have	NULL
opposing	NULL
effects	NULL
on	NULL
the	NULL
response	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
stimulation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:459.	NULL
.	NULL

Kearney	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
T.	NULL
L.	NULL
Walnuas	NULL
,	NULL
R.	NULL
W.	NULL
Kam	NULL
,	NULL
P.	NULL
A.	NULL
Morton	NULL
,	NULL
D.	NULL
Y.	NULL
Loh	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
,	NULL
and	NULL
M.	NULL
K.	NULL
Jenkins	NULL
.	NULL

1995	NULL
.	NULL

Antigen-dependent	NULL
clonal	NULL
expansion	NULL
of	NULL
a	NULL
trace	NULL
population	NULL
of	NULL
antigen-specific	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
is	NULL
dependent	NULL
on	NULL
CD28	NULL
costimulation	NULL
and	NULL
inhibited	NULL
by	NULL
CTLA-4	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:1032	NULL
.	NULL

Krummel	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
T.	NULL
J.	NULL
Sullivan	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1996	NULL
.	NULL

Superantigen	NULL
responses	NULL
and	NULL
co-stimulation	NULL
:	NULL
CD28	NULL
and	NULL
CTLA-4	NULL
have	NULL
opposing	NULL
effects	NULL
on	NULL
T	NULL
cell	NULL
expansion	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

8:519	NULL
.	NULL

Leach	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
M.	NULL
F.	NULL
Krummel	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1996	NULL
.	NULL

Enhancement	NULL
of	NULL
antitumor	NULL
immunity	NULL
by	NULL
CTLA-4	NULL
blockade	NULL
.	NULL

Science	NULL
271:1734	NULL
.	NULL

Kwon	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Hurwitz	NULL
,	NULL
B	NULL
.	NULL

A	NULL
.	NULL

Foster	NULL
,	NULL
C.	NULL
Madias	NULL
,	NULL
A.	NULL
L.	NULL
Feldhaus	NULL
,	NULL
N.	NULL
M.	NULL
Greenberg	NULL
,	NULL
M.	NULL
B.	NULL
Burg	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1997	NULL
.	NULL

Manipulation	NULL
of	NULL
T	NULL
cell	NULL
costimulatory	NULL
and	NULL
inhibitory	NULL
signals	NULL
for	NULL
immunotherapy	NULL
of	NULL
prostate	NULL
cancer	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:8099	NULL
.	NULL

McCoy	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Camberis	NULL
,	NULL
and	NULL
G.	NULL
Le	NULL
Gros	NULL
.	NULL

1997	NULL
.	NULL

Protective	NULL
immunity	NULL
to	NULL
nematode	NULL
infection	NULL
is	NULL
induced	NULL
by	NULL
CTLA-4	NULL
blockade	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:183	NULL
.	NULL

Chambers	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1997	NULL
.	NULL

Co-stimulation	NULL
in	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

9:396	NULL
.	NULL

Liihder	NULL
,	NULL
F.	NULL
,	NULL
P.	NULL
Hoglund	NULL
,	NULL
J.	NULL
P.	NULL
Allison	NULL
,	NULL
C.	NULL
Benoist	NULL
,	NULL
and	NULL
D.	NULL
Mathis	NULL
.	NULL

1998	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocyte-associated	NULL
antigen	NULL
4	NULL
(	NULL
CTLA-4	NULL
)	NULL
regulates	NULL
the	NULL
unfolding	NULL
of	NULL
autoimmune	NULL
diabetes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:427	NULL
.	NULL

Walunas	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
A.	NULL
I.	NULL
Sperling	NULL
,	NULL
R.	NULL
Khattri	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
.	NULL

1996	NULL
.	NULL

CD28	NULL
expression	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
positive	NULL
and	NULL
negative	NULL
selection	NULL
of	NULL
thymocytes	NULL
or	NULL
peripheral	NULL
T	NULL
cell	NULL
tolerance	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:1006	NULL
.	NULL

Krummel	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1996	NULL
.	NULL

CTLA-4	NULL
engagement	NULL
inhibits	NULL
IL-2	NULL
accumulation	NULL
and	NULL
cell	NULL
cycle	NULL
progression	NULL
upon	NULL
activation	NULL
of	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:2533	NULL
.	NULL

Blair	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
J.	NULL
L.	NULL
Riley	NULL
,	NULL
B.	NULL
L.	NULL
Levine	NULL
,	NULL
K.	NULL
P.	NULL
Lee	NULL
,	NULL
N.	NULL
Craighead	NULL
,	NULL
T.	NULL
Francomano	NULL
,	NULL
S.	NULL
J.	NULL
Perfetto	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
B.	NULL
M.	NULL
Carreno	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
June	NULL
.	NULL

1998	NULL
.	NULL

CTLA-4	NULL
ligation	NULL
delivers	NULL
a	NULL
unique	NULL
signal	NULL
to	NULL
resting	NULL
human	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
inhibits	NULL
interleukin-2	NULL
secretion	NULL
but	NULL
allows	NULL
Bcl-X	NULL
;	NULL
,	NULL
induction	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:12	NULL
.	NULL

Green	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
J.	NULL
Noel	NULL
,	NULL
A.	NULL
I	NULL
Sperling	NULL
,	NULL
T.	NULL
L.	NULL
Walunas	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1994	NULL
.	NULL

Absence	NULL
of	NULL
B7-dependent	NULL
responses	NULL
in	NULL
CD28-deficient	NULL
mice	NULL
.	NULL

Immunity	NULL
1:501	NULL
.	NULL

Saito	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
Sakurai	NULL
,	NULL
J.	NULL
Obata	NULL
,	NULL
T.	NULL
Kohsaka	NULL
,	NULL
H.	NULL
Hashimoto	NULL
,	NULL
K.	NULL
Okumura	NULL
,	NULL
R.	NULL
Abe	NULL
,	NULL
and	NULL
M.	NULL
Azuma	NULL
.	NULL

1998	NULL
.	NULL

Involvement	NULL
of	NULL
CD40	NULL
ligand-CD40	NULL
and	NULL
CTLA-4/B7	NULL
pathways	NULL
in	NULL
murine	NULL
acute	NULL
graft-versus-host	NULL
disease	NULL
induced	NULL
by	NULL
allogeneic	NULL
T	NULL
cells	NULL
lacking	NULL
CD28	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:4225	NULL
.	NULL

Lin	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
C.	NULL
Rathmell	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
J.	NULL
M.	NULL
Leiden	NULL
,	NULL
and	NULL
M.-L.	NULL
Alegre	NULL
.	NULL

1998	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
4	NULL
(	NULL
CTLA-4	NULL
)	NULL
blockade	NULL
accelerates	NULL
the	NULL
acute	NULL
rejection	NULL
of	NULL
cardiac	NULL
allografts	NULL
in	NULL
CD28-deficient	NULL
mice	NULL
:	NULL
CTLA-4	NULL
can	NULL
function	NULL
independently	NULL
of	NULL
CD28	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188:199	NULL
.	NULL

Fallarino	NULL
,	NULL
F.	NULL
,	NULL
P.	NULL
E.	NULL
Fields	NULL
,	NULL
and	NULL
T.	NULL
F.	NULL
Gajewski	NULL
.	NULL

1998	NULL
.	NULL

B7-1	NULL
engagement	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
4	NULL
inhibits	NULL
T	NULL
cell	NULL
activation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD28	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188:205	NULL
.	NULL

Waterhouse	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
M.	NULL
Penninger	NULL
,	NULL
E.	NULL
Timms	NULL
,	NULL
A.	NULL
Wakeham	NULL
,	NULL
A.	NULL
Shahinian	NULL
,	NULL
K.	NULL
P.	NULL
Lee	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
H.	NULL
Griesser	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Mak	NULL
.	NULL

1995	NULL
.	NULL

CTLA-4	NULL
deficiency	NULL
causes	NULL
lymphoproliferative	NULL
disorder	NULL
with	NULL
early	NULL
lethality	NULL
.	NULL

Science	NULL
270:985	NULL
.	NULL

Tivol	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
F.	NULL
Borriello	NULL
,	NULL
A.	NULL
N.	NULL
Schweitzer	NULL
,	NULL
W.	NULL
P.	NULL
Lynch	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
,	NULL
and	NULL
A.	NULL
H.	NULL
Sharpe	NULL
.	NULL

1995	NULL
.	NULL

Loss	NULL
of	NULL
CTLA-4	NULL
leads	NULL
to	NULL
massive	NULL
lymphoproliferation	NULL
and	NULL
fatal	NULL
multiorgan	NULL
tissue	NULL
destruction	NULL
,	NULL
revealing	NULL
a	NULL
critical	NULL
negative	NULL
regulatory	NULL
role	NULL
for	NULL
CTLA-4	NULL
.	NULL

Immunity	NULL
3:541	NULL
.	NULL

Chambers	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
D.	NULL
Cado	NULL
,	NULL
T.	NULL
Truong	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1997	NULL
.	NULL

Thymocyte	NULL
differentiation	NULL
is	NULL
normal	NULL
in	NULL
the	NULL
CTLA-4-deficient	NULL
mice	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:9296	NULL
.	NULL

Waterhouse	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
E.	NULL
Bachmann	NULL
,	NULL
J.	NULL
M.	NULL
Penninger	NULL
,	NULL
P.	NULL
S.	NULL
Ohashi	NULL
,	NULL
and	NULL
T.	NULL
W.	NULL
Mak	NULL
.	NULL

1997	NULL
.	NULL

Normal	NULL
thymic	NULL
selection	NULL
,	NULL
normal	NULL
viability	NULL
and	NULL
decreased	NULL
lymphoproliferation	NULL
in	NULL
T	NULL
cell	NULL
receptor-transgenic	NULL
CTLA-4-deficient	NULL
mice	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27	NULL
;	NULL
1887	NULL
.	NULL

Chambers	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
T.	NULL
J.	NULL
Sullivan	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1997	NULL
.	NULL

Lymphoproliferation	NULL
in	NULL
CTLA-4-deficient	NULL
mice	NULL
is	NULL
mediated	NULL
by	NULL
costimulation-dependent	NULL
activation	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Immunity	NULL
7:885	NULL
.	NULL

Tivol	NULL
,	NULL
E.	NULL
,	NULL
S.	NULL
D.	NULL
Boyd	NULL
,	NULL
S.	NULL
McKeon	NULL
,	NULL
F.	NULL
Borriello	NULL
,	NULL
P.	NULL
Nickerson	NULL
,	NULL
T.	NULL
B.	NULL
Strom	NULL
,	NULL
and	NULL
A.	NULL
Sharpe	NULL
.	NULL

1997	NULL
.	NULL

CTLA-4lg	NULL
prevents	NULL
lymphoproliferation	NULL
and	NULL
fatal	NULL
multiorgan	NULL
tissue	NULL
destruction	NULL
in	NULL
CTLA-4-deficient	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:5091	NULL
.	NULL

Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
D.	NULL
B.	NULL
Lombard	NULL
,	NULL
C.	NULL
D.	NULL
Gimmi	NULL
,	NULL
S.	NULL
A.	NULL
Brod	NULL
,	NULL
K.	NULL
Lee	NULL
,	NULL
J.	NULL
C.	NULL
Laning	NULL
,	NULL
D.	NULL
A.	NULL
Hafler	NULL
,	NULL
M.	NULL
E.	NULL
Dorf	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
H.	NULL
Reiser	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
.	NULL

CTLA-4	NULL
and	NULL
CD28	NULL
mRNA	NULL
are	NULL
coexpressed	NULL
in	NULL
most	NULL
T	NULL
cells	NULL
after	NULL
activation	NULL
:	NULL
evidence	NULL
of	NULL
CTLA-4	NULL
and	NULL
CD28	NULL
mRNA	NULL
does	NULL
not	NULL
correlate	NULL
with	NULL
the	NULL
pattern	NULL
of	NULL
lymphokine	NULL
production	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:3795	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
K.	NULL
P.	NULL
Lee	NULL
,	NULL
E.	NULL
S.	NULL
Harris	NULL
,	NULL
B.	NULL
Petryniak	NULL
,	NULL
N.	NULL
Craighead	NULL
,	NULL
P.	NULL
J.	NULL
Reynolds	NULL
,	NULL
D.	NULL
B.	NULL
Lombard	NULL
,	NULL
G.	NULL
J.	NULL
Freeman	NULL
,	NULL
L.	NULL
M.	NULL
Nadler	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
C.	NULL
B.	NULL
Thompson	NULL
,	NULL
and	NULL
C.	NULL
H.	NULL
June	NULL
.	NULL

1993	NULL
.	NULL

Characterization	NULL
of	NULL
CTLA-4	NULL
structure	NULL
and	NULL
expression	NULL
on	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:3489	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
J.	NULL
L.	NULL
Greene	NULL
,	NULL
P.	NULL
Tan	NULL
,	NULL
J.	NULL
Bradshaw	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
C.	NULL
Anasetti	NULL
,	NULL
and	NULL
N.	NULL
K.	NULL
Damle	NULL
.	NULL

1992	NULL
.	NULL

Coexpression	NULL
and	NULL
functional	NULL
cooperativity	NULL
of	NULL
CTLA-4	NULL
and	NULL
CD28	NULL
on	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:1595	NULL
.	NULL

Perkins	NULL
,	NULL
D.	NULL
,	NULL
Z.	NULL
Wang	NULL
,	NULL
C.	NULL
Donovan	NULL
,	NULL
H.	NULL
He	NULL
,	NULL
D.	NULL
Mark	NULL
,	NULL
G.	NULL
Guan	NULL
,	NULL
Y.	NULL
Wang	NULL
,	NULL
T.	NULL
Walunas	NULL
,	NULL
J.	NULL
Bluestone	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
A.	NULL
Listman	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
CTLA-4	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:4154	NULL
.	NULL

Alegre	NULL
,	NULL
M.-L.	NULL
,	NULL
P.	NULL
J.	NULL
Noel	NULL
,	NULL
B.	NULL
J.	NULL
Eisfelder	NULL
,	NULL
E.	NULL
Chuang	NULL
,	NULL
M.	NULL
R.	NULL
Clark	NULL
,	NULL
S.	NULL
L.	NULL
Reiner	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
surface	NULL
and	NULL
intracellular	NULL
expression	NULL
of	NULL
CTLA-4	NULL
on	NULL
mouse	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:4762	NULL
.	NULL

Jenkins	NULL
,	NULL
M.	NULL
K.	NULL
1994	NULL
.	NULL

The	NULL
ups	NULL
and	NULL
downs	NULL
of	NULL
costimulation	NULL
.	NULL

Immunity	NULL
1:443	NULL
.	NULL

Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
G.	NULL
J.	NULL
Freeman	NULL
,	NULL
V.	NULL
A.	NULL
Boussiotis	NULL
,	NULL
P.	NULL
Rennert	NULL
,	NULL
C.	NULL
J.	NULL
Jellis	NULL
,	NULL
E.	NULL
Greenfield	NULL
,	NULL
M.	NULL
Barber	NULL
,	NULL
V.	NULL
A.	NULL
Restivo	NULL
,	NULL
X.	NULL
Ke	NULL
,	NULL
G.	NULL
S.	NULL
Gray	NULL
,	NULL
and	NULL
L.	NULL
M.	NULL
Nadler	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5820	NULL
36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

1995	NULL
.	NULL

CTLA-4	NULL
mediates	NULL
antigen-specific	NULL
apoptosis	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:811	NULL
.	NULL

Linsley	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
role	NULL
of	NULL
the	NULL
CD28	NULL
receptor	NULL
during	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
antigen	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

11:191	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Ledbetter	NULL
,	NULL
G.	NULL
Stella	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
of	NULL
lymphokine	NULL
messenger	NULL
RNA	NULL
stability	NULL
by	NULL
a	NULL
surface-mediated	NULL
T	NULL
cell	NULL
activation	NULL
pathway	NULL
.	NULL

Science	NULL
244:339	NULL
.	NULL

Umlauf	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
B.	NULL
Beverly	NULL
,	NULL
O.	NULL
Lantz	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schwartz	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
by	NULL
CD28	NULL
costimulation	NULL
in	NULL
mouse	NULL
T-cell	NULL
clones	NULL
:	NULL
both	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
RNAs	NULL
are	NULL
regulated	NULL
with	NULL
complex	NULL
kinetics	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:3197	NULL
.	NULL

Brorson	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
B.	NULL
Beverley	NULL
,	NULL
S.	NULL
M.	NULL
Kang	NULL
,	NULL
M.	NULL
Lenardo	NULL
,	NULL
and	NULL
R.	NULL
H.	NULL
Schwartz	NULL
.	NULL

1991	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
cytokine	NULL
genes	NULL
in	NULL
nontransformed	NULL
T	NULL
cells	NULL
:	NULL
apparent	NULL
constitutive	NULL
signals	NULL
in	NULL
run-on	NULL
assays	NULL
can	NULL
be	NULL
caused	NULL
by	NULL
repeat	NULL
sequences	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:3601	NULL
.	NULL

Rooney	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
T.	NULL
Hoey	NULL
,	NULL
and	NULL
L.	NULL
H.	NULL
Glimcher	NULL
.	NULL

1995	NULL
.	NULL

Coordinate	NULL
and	NULL
cooperative	NULL
roles	NULL
for	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
murine	NULL
IL-4	NULL
gene	NULL
.	NULL

Immunity	NULL
2:473	NULL
.	NULL

Sherr	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Roberts	NULL
.	NULL

1995	NULL
.	NULL

Inhibitors	NULL
of	NULL
mammalian	NULL
G1	NULL
cyclin-dependent	NULL
kinases	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:1149	NULL
.	NULL

Chaffin	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
C.	NULL
R.	NULL
Beals	NULL
,	NULL
T.	NULL
M.	NULL
Wilkie	NULL
,	NULL
K.	NULL
A.	NULL
Forbush	NULL
,	NULL
M.	NULL
I.	NULL
Simon	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Perlmutter	NULL
.	NULL

1990	NULL
.	NULL

Dissection	NULL
of	NULL
thymocyte	NULL
signaling	NULL
pathways	NULL
by	NULL
in	NULL
vivo	NULL
expression	NULL
of	NULL
pertussis	NULL
toxin	NULL
ADP-ribosyltransferase	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:3821	NULL
.	NULL

Novak	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
P.	NULL
M.	NULL
White	NULL
,	NULL
and	NULL
E.	NULL
V.	NULL
Rothenberg	NULL
.	NULL

1990	NULL
.	NULL

Regulatory	NULL
anatomy	NULL
of	NULL
the	NULL
murine	NULL
interleukin-2	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:4523.	NULL
.	NULL

Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
,	NULL
and	NULL
W.	NULL
T.	NULL
Garrard	NULL
.	NULL

1986	NULL
.	NULL

Chromosomal	NULL
loop	NULL
anchorage	NULL
of	NULL
the	NULL
k	NULL
immunoglobulin	NULL
gene	NULL
occurs	NULL
next	NULL
to	NULL
the	NULL
enhancer	NULL
in	NULL
a	NULL
region	NULL
containing	NULL
to-poisomerase	NULL
II	NULL
.	NULL

Cell	NULL
44:273	NULL
.	NULL

Allison	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
W.	NULL
L.	NULL
Havran	NULL
,	NULL
M.	NULL
Poenie	NULL
,	NULL
J.	NULL
Kimura	NULL
,	NULL
L.	NULL
Degraffenreid	NULL
,	NULL
S.	NULL
Ajami	NULL
,	NULL
G.	NULL
Duwe	NULL
,	NULL
A.	NULL
Weiss	NULL
,	NULL
and	NULL
R.	NULL
Tsien	NULL
.	NULL

1987	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
CD3	NULL
on	NULL
murine	NULL
thymocytes	NULL
.	NULL

In	NULL
The	NULL
T	NULL
Cell	NULL
Receptor	NULL
,	NULL
UCLA	NULL
Symposia	NULL
on	NULL
Molecular	NULL
and	NULL
Cellular	NULL
Biology	NULL
,	NULL
New	NULL
Series	NULL
.	NULL

J.	NULL
Kappler	NULL
,	NULL
and	NULL
M.	NULL
Davis	NULL
,	NULL
eds	NULL
.	NULL

Alan	NULL
R.	NULL
Liss	NULL
,	NULL
New	NULL
York	NULL
,	NULL
p.	NULL
33	NULL
.	NULL

Gross	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
E.	NULL
Callas	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
and	NULL
distribution	NULL
of	NULL
the	NULL
costimulatory	NULL
receptor	NULL
CD28	NULL
in	NULL
the	NULL
mouse	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:380	NULL
.	NULL

Havran	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
S.	NULL
Grell	NULL
,	NULL
G.	NULL
Duwe	NULL
,	NULL
J.	NULL
Kimura	NULL
,	NULL
A.	NULL
Wilson	NULL
,	NULL
A.	NULL
M.	NULL
Kruisbeck	NULL
,	NULL
R.	NULL
L.	NULL
O'Brien	NULL
,	NULL
W.	NULL
Born	NULL
,	NULL
R.	NULL
E.	NULL
Tigelaar	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1989	NULL
.	NULL

Limited	NULL
diversity	NULL
of	NULL
T-cell	NULL
receptor	NULL
y-chain	NULL
expression	NULL
of	NULL
murine	NULL
Thy-1*	NULL
dendritic	NULL
epidermal	NULL
cells	NULL
revealed	NULL
by	NULL
Vy3-specific	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
:	NULL
4185	NULL
.	NULL

Ozato	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Sachs	NULL
.	NULL

1981	NULL
.	NULL

Monoclonal	NULL
antibodies	NULL
to	NULL
mouse	NULL
MHC	NULL
anti-gens	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

126:317	NULL
.	NULL

Symington	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
J.	NULL
Sprent	NULL
.	NULL

1981	NULL
.	NULL

A	NULL
monoclonal	NULL
antibody	NULL
detecting	NULL
an	NULL
Ia	NULL
specificity	NULL
mapping	NULL
in	NULL
the	NULL
I-A	NULL
or	NULL
I-E	NULL
subregion	NULL
.	NULL

Immunogenetics	NULL
14:53	NULL
.	NULL

Sarmiento	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Glasebrook	NULL
,	NULL
and	NULL
F.	NULL
W.	NULL
Fitch	NULL
.	NULL

1980	NULL
.	NULL

IgG	NULL
or	NULL
IgM	NULL
monoclonal	NULL
antibodies	NULL
reactive	NULL
with	NULL
different	NULL
determinants	NULL
on	NULL
the	NULL
molecular	NULL
complex	NULL
bearing	NULL
Lyt2	NULL
antigen	NULL
block	NULL
T	NULL
cell-mediated	NULL
cytolysis	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
complement	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

125:2665	NULL
.	NULL

Murray	NULL
,	NULL
L.	NULL
J.	NULL
,	NULL
R.	NULL
Lee	NULL
,	NULL
and	NULL
C.	NULL
Martens	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
vivo	NULL
cytokine	NULL
gene	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
the	NULL
autoimmune	NULL
MRL/mp-lpr/lpr	NULL
mouse	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

20:163	NULL
.	NULL

Platzer	NULL
,	NULL
C.	NULL
,	NULL
G.	NULL
Richter	NULL
,	NULL
K.	NULL
Uberla	NULL
,	NULL
W.	NULL
Muller	NULL
,	NULL
H.	NULL
Blocker	NULL
,	NULL
T.	NULL
Diamantstein	NULL
,	NULL
and	NULL
T.	NULL
Blankenstein	NULL
.	NULL

1992	NULL
.	NULL

Analysis	NULL
of	NULL
cytokine	NULL
mRNA	NULL
levels	NULL
in	NULL
interleukin-4	NULL
transgenic	NULL
mice	NULL
by	NULL
quantitative	NULL
polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

22:1179	NULL
.	NULL

Brunner	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Larsen	NULL
,	NULL
A.	NULL
Sette	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Mitchison	NULL
.	NULL

1995	NULL
.	NULL

Altered	NULL
Th1/Th2	NULL
balance	NULL
associated	NULL
with	NULL
the	NULL
immunosuppressive/protective	NULL
effect	NULL
of	NULL
the	NULL
HSA	NULL
``	NULL
allele	NULL
on	NULL
the	NULL
response	NULL
to	NULL
allo-HPPD	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25:3285	NULL
.	NULL

INHIBITION	NULL
OF	NULL
EARLY	NULL
T	NULL
CELL	NULL
ACTIVATION	NULL
BY	NULL
CTLA-4	NULL
54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

71	NULL
.	NULL

Woronicz	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
A.	NULL
Lina	NULL
,	NULL
B.	NULL
J.	NULL
Calnan	NULL
,	NULL
S.	NULL
Szychowski	NULL
,	NULL
L.	NULL
Cheng	NULL
,	NULL
and	NULL
A.	NULL
Winoto	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
Nur77	NULL
orphan	NULL
receptor	NULL
in	NULL
activation-induced	NULL
apoptosis	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:6364	NULL
.	NULL

Chan	NULL
,	NULL
F.	NULL
K.-M.	NULL
,	NULL
J.	NULL
Zhang	NULL
,	NULL
L.	NULL
Cheng	NULL
,	NULL
D.	NULL
N.	NULL
Shapiro	NULL
,	NULL
and	NULL
A.	NULL
Winoto	NULL
.	NULL

1995	NULL
.	NULL

Identification	NULL
of	NULL
human	NULL
and	NULL
mouse	NULL
p19	NULL
,	NULL
a	NULL
novel	NULL
CDK4	NULL
and	NULL
CDK6	NULL
inhibitor	NULL
with	NULL
homolog	NULL
to	NULL
p16***	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:2682	NULL
.	NULL

Lucas	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
A.	NULL
Szepesi	NULL
,	NULL
J.	NULL
F.	NULL
Modiano	NULL
,	NULL
J.	NULL
Domenico	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Gelfand	NULL
.	NULL

1995	NULL
.	NULL

Regulation	NULL
of	NULL
synthesis	NULL
and	NULL
activity	NULL
of	NULL
the	NULL
PLSTIRE	NULL
protein	NULL
(	NULL
cyclin-dependent	NULL
kinase	NULL
6	NULL
(	NULL
cdk6	NULL
)	NULL
,	NULL
a	NULL
major	NULL
cyclin	NULL
D-associated	NULL
edk4	NULL
homologue	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

154:6275	NULL
.	NULL

Lucas	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
A.	NULL
Szepesi	NULL
,	NULL
J.	NULL
Domenico	NULL
,	NULL
A.	NULL
Tordai	NULL
,	NULL
N.	NULL
Terada	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Gelfand	NULL
.	NULL

1995	NULL
.	NULL

Differential	NULL
regulation	NULL
of	NULL
the	NULL
synthesis	NULL
and	NULL
activity	NULL
of	NULL
the	NULL
major	NULL
cyclin-dependent	NULL
kinases	NULL
,	NULL
p34cdc2	NULL
,	NULL
p33cdk2	NULL
,	NULL
p34cdk4	NULL
,	NULL
during	NULL
cell	NULL
cycle	NULL
entry	NULL
and	NULL
progression	NULL
in	NULL
normal	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

165:406	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Loh	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1995	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

Curr	NULL
.	NULL

Biol	NULL
.	NULL

7:333	NULL
.	NULL

Northrop	NULL
,	NULL
L.	NULL
P.	NULL
,	NULL
S.	NULL
N.	NULL
Ho	NULL
,	NULL
L.	NULL
Chen	NULL
,	NULL
D.	NULL
J.	NULL
Thomas	NULL
,	NULL
L.	NULL
A.	NULL
Timmerman	NULL
,	NULL
G.	NULL
P.	NULL
Nolan	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1994	NULL
.	NULL

NF-AT	NULL
components	NULL
define	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
targeted	NULL
in	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
369:497	NULL
.	NULL

Firpo	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
A.	NULL
Koff	NULL
,	NULL
M.	NULL
J.	NULL
Solomon	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Roberts	NULL
.	NULL

1994	NULL
.	NULL

Inactivation	NULL
of	NULL
a	NULL
Cdk2	NULL
inhibitor	NULL
during	NULL
interleukin	NULL
2-induced	NULL
proliferation	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:4889	NULL
.	NULL

Nourse	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
Firpo	NULL
,	NULL
W.	NULL
M.	NULL
Flanagan	NULL
,	NULL
S.	NULL
Coats	NULL
,	NULL
K.	NULL
Polyak	NULL
,	NULL
M.	NULL
H.	NULL
Lee	NULL
,	NULL
J.	NULL
Massague	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Roberts	NULL
.	NULL

1994	NULL
.	NULL

Interleukin	NULL
2-mediated	NULL
elimination	NULL
of	NULL
the	NULL
p27Kip1	NULL
cyclin-dependent	NULL
kinase	NULL
inhibitor	NULL
prevented	NULL
by	NULL
rapa-mycin	NULL
.	NULL

Nature	NULL
372:570	NULL
.	NULL

Meyerson	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
E.	NULL
Harlow	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
of	NULL
G1	NULL
kinase	NULL
activity	NULL
for	NULL
cdk6	NULL
,	NULL
a	NULL
novel	NULL
cyclin	NULL
D	NULL
partner	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14:2077	NULL
.	NULL

Modiano	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
J.	NULL
Domenico	NULL
,	NULL
A.	NULL
Szepesi	NULL
,	NULL
N.	NULL
Terada	NULL
,	NULL
J.	NULL
J.	NULL
Lucas	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Gelfand	NULL
.	NULL

1995	NULL
.	NULL

Symmetry	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
cyclin-dependent	NULL
kinases	NULL
in	NULL
mitogen	NULL
and	NULL
growth	NULL
factor-stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Ann	NULL
.	NULL

NY	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

766:134.	NULL
.	NULL

Modiano	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
J.	NULL
Domenicao	NULL
,	NULL
A.	NULL
Szepeso	NULL
,	NULL
J.	NULL
J.	NULL
Lucas	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Gelfand	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
requirements	NULL
for	NULL
interleukin-2	NULL
distinguish	NULL
the	NULL
expression	NULL
and	NULL
activity	NULL
of	NULL
the	NULL
cyclin-dependent	NULL
kinases	NULL
cdk4	NULL
and	NULL
cdk2	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:2972	NULL
.	NULL

Calvo	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
D.	NULL
Amsen	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Kruisbeek	NULL
.	NULL

1997	NULL
.	NULL

Cytotoxic	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
4	NULL
(	NULL
CTLA-4	NULL
)	NULL
interferes	NULL
with	NULL
extracellular	NULL
signal-regulated	NULL
kinase	NULL
(	NULL
ERK	NULL
)	NULL
and	NULL
Jun	NULL
NH	NULL
,	NULL
-terminal	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
activation	NULL
,	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
phosphoryla-tion	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
£	NULL
and	NULL
ZAP7O	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1645	NULL
.	NULL

Bachmann	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
P.	NULL
Waterhouse	NULL
,	NULL
D.	NULL
E.	NULL
Speiser	NULL
,	NULL
McKall-Faienza	NULL
,	NULL
T.	NULL
W.	NULL
Mak	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Ohashi	NULL
.	NULL

1998	NULL
.	NULL

Normal	NULL
responsiveness	NULL
of	NULL
CTLA-4-deficient	NULL
anti-viral	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:95	NULL
.	NULL

Chambers	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
T.	NULL
J.	NULL
Sullivan	NULL
,	NULL
T.	NULL
Truong	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1998	NULL
.	NULL

Secondary	NULL
but	NULL
not	NULL
primary	NULL
T	NULL
cell	NULL
responses	NULL
are	NULL
enhanced	NULL
in	NULL
CTLA-4-deficient	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28:3137	NULL
.	NULL

Walunas	NULL
,	NULL
T.	NULL
L.	NULL
,	NULL
C.	NULL
Y.	NULL
Bakker	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
.	NULL

1996	NULL
.	NULL

CTLA-4-ligation	NULL
blocks	NULL
CD28-dependent	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:2541	NULL
.	NULL

Shapiro	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
K.	NULL
E.	NULL
Truitt	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Imboden	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1997	NULL
.	NULL

CD28	NULL
mediates	NULL
transcriptional	NULL
upregulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
promoter	NULL
through	NULL
a	NULL
composite	NULL
element	NULL
containing	NULL
the	NULL
CD28RE	NULL
and	NULL
NF-IL-2B	NULL
AP-1	NULL
sites	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:4051	NULL
.	NULL

Su	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
M.	NULL
Jacinto	NULL
,	NULL
T.	NULL
Hibi	NULL
,	NULL
T.	NULL
Kallunki	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
Y.	NULL
Ben-Neriah	NULL
.	NULL

1994	NULL
.	NULL

JNK	NULL
is	NULL
involved	NULL
in	NULL
signal	NULL
integration	NULL
during	NULL
costimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
77:727	NULL
.	NULL

Tusto	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
O.	NULL
Acuto	NULL
.	NULL

1998	NULL
.	NULL

CD28	NULL
affects	NULL
the	NULL
earliest	NULL
signaling	NULL
events	NULL
generated	NULL
by	NULL
TCR	NULL
engagement	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28:2131	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

